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Abstract
Cancer continues to be the leading cause of death in Canada. Many conventional chemotherapies
have indicated side effects due to a lack of treatment specificity and are thus not suitable for longterm usage. Natural health products (NHPs) are well-tolerated and safe for consumption, and some
have pharmaceutical uses particularly for their anti-cancer effects.
We have previously investigated the anti-cancer efficacy of dandelion (Taraxacum officinale) root,
lemongrass (Cymbopogon citratus), and hibiscus (Hibiscus syriacus) extracts. However, their
efficacy on prostate, colorectal, and breast cancer as well as their interactions with standard
chemotherapeutics have not been studied to determine if they will be suitable for adjuvant
therapies. If successful, these extracts could potentially be used in conjunction with
chemotherapeutics to minimize the risk of drug-related toxicity and enhance the efficacy of the
treatment. This work aimed evaluate the efficacy and mechanism of apoptotic induction in various
cancer cells, assess the drug-drug interactions of NHPs and chemotherapeutics, and investigate the
effects of these NHPs on tumour xenografted mice models.
Using standard biochemical and morphological assays, we have demonstrated that dandelion root
extract (DRE), lemongrass extract (LGE), and hibiscus extract (HE) exhibit selective anti-cancer
activity. These extracts were also able to enhance the anticancer efficacy of common
chemotherapeutics and protect normal healthy cells from toxicity. In mice xenografted with human
cancer cells, DRE and LGE were able to reduce tumour burden and LGE was able to enhance
FOLFOX activity. Thus, the implementation of these well-tolerated extracts in adjuvant therapies
could be a selective and efficacious approach to cancer treatment. These findings provide scientific
validation to support the safe and effective use of NHPs as well-tolerated and effective forms of
cancer treatment.
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Chapter 1
General Introduction

Containing work from:

Exploiting mitochondrial vulnerabilities to trigger apoptosis selectively
in cancer cells

Christopher Nguyen1 and Siyaram Pandey1

1

Department of Chemistry and Biochemistry, University of Windsor, Windsor, Ontario N9B
3P4, Canada

Oxidative Medicine and Cellular Longevity (2019)

1.1

Cancer
Despite many advances in cancer treatment approaches, cancer continues to remain the

leading cause of death in both Canada and the United States [1,2]. In Canada, of 206,200 projected
cancer incidences, 1 in 4 diagnosed patients were expected to succumb to the disease in 2018 [1].
In the United States, 1,762,450 new cancer cases are projected to be diagnosed, with about 1 in 3
diagnosed patients expected to succumb to the disease in 2019 [2].
Cancer is a disease characterized by uncontrolled cell growth and proliferation resulting
from evasion of regulatory mechanisms in cells [3]. Cancer is a multi-step process involving many
genetic changes due to mutation of the genome. Genetic changes to 350 of the 22,000 protein
coding genes have been determined to be involved in and contribute to cancer development [4].
These genes can be categorized into two categories, tumour suppressor genes and oncogenes.
Tumour-suppressor genes encode proteins that are able to inhibit cell proliferation, and thus their
knockdown via mutation may lead to development of cancer [5]. For example, p53 encodes a
protein able to transmit a variety of stress-inducing signals to induce different anti-proliferative
cellular responses leading to cell death. Inactivation of p53 in cancer is a characteristic checkpoint
in cancer, allowing for uncontrolled cancer cell proliferation [6]. Oncogenes encode proteins that
are able to transform cells supporting the progression of cancer development. For example, the
Ras oncogene is responsible for causing a metabolic swap from oxidative phosphorylation to
glycolysis to enable reprogramming of cancer cell metabolism [7].
Hanahan and Weinberg proposed hallmarks of cancerous cells that allow for these cells to
be distinguished from non-cancerous cells (Figure 1) [3]. In later years, this list was modified to
include additional characteristics (Figure 2) [8]. These hallmarks are essential to allow for cancer
cell growth and survival, allowing them to evade safeguarding mechanisms from the body. This

2

theory identifies the genomic changes and defining characteristics that promote progressive
transformation of normal healthy cells into malignant cancer cells. These hallmarks include:
I.

Sustaining proliferative signaling through the generation of oncogenes which are able to
eliminate normal cell signaling dependence through their growth signals capabilities.

II.

Evading growth suppressors that negatively regulate cell proliferation. This is through the
suppression or disruption of tumour suppressor genes capable of regulating proliferation.

III.

Bypassing cell death signaling to resist cell death through the overexpression of prosurvival proteins such as the Bcl-2 family of proteins.

IV.

Enabling replicative immortality to maintain replicative signaling usually by up-regulating
the expression of telomerase enzyme to inhibit telomere shortening.

V.

Inducing the development of new blood vessels (angiogenesis) to allow for a continuous
supply of oxygen and nutrients through the up-regulation of proteins such as vascular
endothelial growth factor.

VI.

Activating metastasis and invading surround tissue, allowing tumour cells to migrate to a
secondary site to establish. This can be done due to alteration of certain protein functions
such as cell adhesion molecules (CAMs) and avoidance of cell-death mechanisms when
metastasizing.

Hanahan and Weinberg have proposed two emerging hallmarks that have been shown to be
involved in the development and progression of some, perhaps all, cancers:
VII.

Reprogramming of energy metabolism in order to fuel cell growth and division. This
allows for the increased energetic needs of cancer cells to be met through an increased
dependence on aerobic glycolysis.
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VIII.

Evading immune destruction from lymphocytes, macrophages, and natural killer cells that
would normally identify cellular dysfunction and react to kill cancer cells. This may also
be done by avoidance of detection by immune system.

Figure 1: The hallmarks of cancer. Six different properties of cancer cells have been attributed to the
progression of cancer in humans. Targeting of these hallmarks may lead to the development of improved cancer
therapeutics (Hanahan & Weinberg, 2011).

Figure 2: Emerging hallmarks of cancer. Further research has suggested that two additional hallmarks of
cancer are now involved in pathogenesis of potentially all cancers (Hanahan and Weinberg, 2011).
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As normal cells progressively move towards a neoplastic state of abnormal cell growth,
they will develop these hallmark capabilities based on the abilities of these traits to allow them to
ultimately become malignant [8]. As cancerous cells progressively express these hallmarks, they
will form tumours, become malignant, undergo metastasis to spread, and eventually lead to
mortality due to cancer [9]. However, these hallmarks additionally provide researchers with
interesting targets when developing treatments that are able to exploit cancer cell dependencies
and induce cell death [3].

5

1.2

Cancer Metabolism: Mitochondria and Cancer
Cancer cells, through the accumulation of many genetic mutations, are notorious for their

enhanced ability to proliferate in suboptimal host conditions. Cancer cells are able to manipulate
metabolic and immunogenic pathways to adapt and operate under difficult conditions [10]. Indeed,
metabolic reprogramming in cancer cells has been identified as a hallmark of cancer and a potential
vulnerability that can be targeted to fight this disease [8].
In order to proliferate in hostile conditions, cancer cells undergo metabolic reprogramming
to meet their energy needs. In the 1920s, Otto Warburg observed the production of excessive
lactate in cancer cells in the presence of oxygen due to ‘oxidative glycolysis’, with the phenomenon
eventually termed the ‘Warburg effect’ [11,12]. However, this has led to the wrong belief that
there is mitochondrial damage and inefficiency in cancer cells, forcing them to rely on excessive
glycolysis for their energy needs [13]. Contrary to this, a large breadth of work has shown that
mitochondria respiration remains undamaged in many cancers, and many cancer cells that exhibit
the Warburg effect retain mitochondrial respiration [14]. Interestingly, in ovarian cancer, the
microenvironment of cancer cells directly impacts their metabolic reprogramming [15]. Peripheral
cells of the tumour spheroid exposed to normal oxygen levels relied heavily on aerobic glycolysis
and were proliferative cells. In contrast, internal cells were poorly vascularized, leading to cell
quiescence and heavy dependence on mitochondrial oxidative phosphorylation (OxPhos) for the
majority of their ATP production [16,17]. This study highlights that the fact that, while standard
chemotherapy was effective at killing proliferative cells, the quiescent cell population is resistant
and causes tumour regeneration. In order to properly combat cancer, a multi-faceted approach
including mitochondria vulnerabilities should be considered to ensure complete tumour
elimination. In fact, recent observations have indicated that mitochondria support and play a
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critical role in tumourigenesis through their metabolic reprogramming, oxidative signaling,
reactive oxygen species generation, and production of oncometabolites [18-21].
Cancer cells have higher metabolic needs and antioxidant defenses compared to healthy
cells. Cancer cells rely heavily on aerobic glycolysis to meet their energy needs, and as a result
upregulate glucose transporters to meet these demands [22,23]. Furthermore, due to aerobic
glycolysis and production of large amounts of lactate and pyruvate leading to increased acidity in
the cytoplasm in cancer cells, the mitochondria are hyperpolarized compared to those of normal
cells [23]. This can also be due to increased intracellular Ca2+ levels and upregulation of antiapoptotic Bcl2 protein [24,25]. The hyperpolarization of the mitochondria has also been attributed
to increased apoptosis evasion as well [25,26].
While the mitochondria are the organelle responsible for ATP generation, they contain a
number of pro-apoptotic factors such as cytochrome c, endonuclease G, and apoptosis inducing
factor (AIF) which can induce cell suicide program if they are released outside. This occurs due to
the depolarization of the mitochondrial membrane potential leading to membrane
permeabilization. Thus, mitochondria in the cell are also a death machinery that can be activated
by its leakage. Release of cytochrome c in the cytosol leads to its association with APAF and
Caspase-9 eventually thus forming the apoptosome which activates Caspase-3 eventually
executing apoptotic cell death [27]. In contrast, AIF-initiated apoptosis is caspase-independent,
through chromatin condensation and DNA fragmentation [28]. The presence of such pro-apoptotic
proteins in the mitochondria highlights the organelle as an interesting target for cancer therapy
research.
Mitochondria play a central role in the apoptosis induction process. It would be appropriate
to say that each mitochondrion acts as a self-destructing button for the cell. In non-cancerous cells,
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the mitochondria are assembled properly, and are generally difficult to permeabilize. However, in
cancer cells, mitochondria could be vulnerable to certain agents that can permeabilize the
membrane [29]. Our research group has hypothesized that, due to rapid proliferation, cancer cells
face a limited resource of lipids, and the assembly of the mitochondrial membrane may be
compromised compared to normal healthy cells. While healthy cells may be resilient to
mitochondrial targeting agents, cancer cells may be especially susceptible to them due to
hyperpolarization of the membrane as well as exposure of certain proteins to these agents resulting
from poor assembly. These overall differences between cancerous and non-cancerous
mitochondria can be targeted to allow for selective apoptosis induction in cancer cells.
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1.3

Targeting Mitochondrial Vulnerabilities
Cancer cells may rely on OxPhos heavily in addition to aerobic glycolysis for their

excessive energy needs [30,31]. Furthermore, the mitochondrial membranes are hyperpolarized
and poorly assembled [32], targeting the mitochondrial vulnerabilities of cancer cells could be an
interesting approach to selectively kill cancer cells. Weinberg and Chandel postulate that, while
cancer cells may simply turn to aerobic glycolysis, there are other reasons supporting
mitochondrial targeting [16]; The first being that poorly perfused tumours may have limited access
to aerobic conditions and glucose, thereby focusing on mitochondrial ATP generation, posing an
excellent target for such drugs [33,34]. Due to their limited access to glucose, cancer cells will turn
to OxPhos because of the increased yield of ATP per glucose molecule. The second being that
some cancer cells indeed show a heavy dependence on OxPhos for their ATP needs [34,35].
Finally, drugs targeting and inhibiting mitochondrial ATP production may synergize positively
with those targeting aerobic glycolysis. In doing so, these drugs may potentially sensitize cancer
cells to aerobic glycolysis-targeting drugs and enhance their action. Further, when the
mitochondria are targeted, leakage of pro-apoptotic factors from mitochondria will result into
activation of apoptotic regardless.
Some vulnerabilities that may be targeted include the induction of oxidative stress on
cancerous mitochondria, targeting modified mitochondrial metabolism, and to sensitize or inhibit
chemoresistant cancer cells.
Induction of oxidative stress as a target for cancer treatment
Reactive oxygen species (ROS) are radicals containing a single unpaired electron in their
outermost electron shell [36]. At lower levels, ROS can be advantageous in promoting proliferation
and signaling [37,38]. However, at higher levels, ROS can induce oxidative stress leading to cell
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death [37]. Cancer cells are believed to require a high concentration of ROS to supplement their
increased proliferation rates, and it has been hypothesized that cancer cells can take advantage of
the resulting augmented DNA-damage to promote further mutation and tumourigenesis [38,39].
The induction of oxidative stress via chemotherapies or radiation therapy on cancer cells may
result in DNA damage-induced cell death [40-43].
The production of ROS in the mitochondria is an inevitability due to its generation as a byproduct in OxPhos, and it plays a role in alteration of mitochondrial dynamics [44]. The production
of ROS in mitochondria is efficiently quenched in normal cells using antioxidative defense system
include superoxide dismutase and glutathione peroxidase [45,46]. If not quenched or eliminated,
the excess oxidative stress can cause further dysfunction of mitochondrial proteins leading to
increased production of ROS, creating a vicious cycle of mitochondrial damage and oxidative
stress, leading to the collapse of the mitochondrial membrane potential (MMP), permeabilization,
and the induction of apoptosis [44].
It would be worthwhile combining mitochondrial targeting agents with oxidative stress
inducers to target cancer cells.
Mitochondrial reprogramming as a target for cancer treatment
Cancer cells rely heavily on aerobic glycolysis for the bulk of their energy needs and turn
to oxidative phosphorylation only in situations such as nutrient deficiencies. Upregulation of
aerobic glycolysis is a result of increased expression of oncogenes (such as MYC and KRAS) and
deregulation of the P13K signaling pathway [47-49]. Due to excessive glycolysis and lactic acid
production, mitochondria are hyperpolarized [23]. By exploiting these changes compared to
normal mitochondrial characteristics, selective and effective treatments can be developed.
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Recent work into targeting of mitochondrial reprogramming vulnerabilities has focused on many
different approaches including inhibition of upregulated metabolic proteins found only in cancer
cells [50], targeting mitochondrial oxidative phosphorylation or respiration [51,52] or through the
induction of antibiotics-induced mitochondrial dysfunction [53].
Sensitization and reversal of chemoresistance by targeting the mitochondria
Cancer cell mitochondria contain higher amounts of anti-apoptotic Bcl2 family of proteins
to evade apoptosis and thus are resistant to anti-cancer drugs. The depletion of mitochondrial DNA
(mtDNA) has been reported in numerous cancers in vivo and has been implicated in increasing the
expression of anti-apoptotic genes such as Bcl2, activating pro-survival enzymes ultimately
leading to resistance to chemotherapy-mediated apoptosis [54-58]. Due to mitochondrial
reprogramming to rely on aerobic glycolysis, cancer cells are able to further resist apoptosis
through upregulation of regulatory enzymes such as mitochondrial hexokinase 2 [59]. Hexokinase
2 has been shown to increase lactate production, cell proliferation, resistance to drugs, and invasion
[60]. Lactate production allows for cancer cells to maintain a slightly acidic micro-environment
and enhance their survival through pathways such as using lactate as an antioxidant [61-63].
Targeting these mitochondrial proteins could remove this resistance, and cancer cells may be
susceptible to cell death [54].
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1.4

Apoptosis
The programmed cell death (PCD) process of apoptosis is able to impede and stop cancer

development and progression and triggered by physiological stressors or extracellular signals [8].
One hallmark of cancer is the ability of cancer cells to avoid these PCD processes through various
mechanisms allowing them to continue proliferation under the same physiological stressors or
signals that would normally induce cell death in healthy cells [8].
Apoptosis is the complex and physiological process of cell death that is used to remove
cells with damaged DNA or unwanted cells. Thus, apoptosis is a safeguard against cancerous
development of a cell containing damaged DNA. Apoptosis can be triggered by DNA damage,
oxidative stress, growth factor deprivation, and mitochondrial depolarization [64]. The knowledge
of biochemical mechanisms of apoptosis have led to developments of therapies targeting cancer
cells to induce cell death. [64]. The exploitation of cellular vulnerabilities in cancerous cells,
including oxidative stress and mitochondrial membrane destabilization, should be used to develop
novel therapeutic agents that could trigger apoptosis and eradicate the disease [65,66]. Since the
discovery of apoptosis, researchers have aimed to exploit cancer cell vulnerabilities to induce
apoptosis selectively in cancer cells. ranging from identification of tumour-suppressor genes,
discovery of novel compounds, and development of technologies such as nanoparticles to
selectively identify targets which will be efficacious and selective for cancer [67-69].
Unfortunately, cancer cells develop resistance to many chemotherapies by resisting apoptosis
and/or exporting the drugs outside the cell. Cancer cells achieve this by disrupting pro-apoptotic
proteins, reducing the function of caspases, and impairing death receptor signalling [64].
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There are two pathways by which apoptosis can initiate and progress – the intrinsic
pathway and the extrinsic pathway, both triggered by different signals, but leading to apoptosis.
The process of apoptosis, both intrinsically and extrinsically are shown in Fig. 3 [70].
The intrinsic pathway (Figure 3) is triggered by internal stressors, including DNA damage,
oxidative stress, developmental cues, lack of growth factors, radiation, toxins, and
chemotherapeutics. These may come via a negative or positive intracellular signal. Negative
signals involve the absence of certain growth factors, hormones and cytokines that can lead to
failure of suppression of death programs, thereby triggering apoptosis whereas positive signals
involve the introduction of a stressor such as radiation, toxins, viral infections, and free radicals
[71]. The intrinsic pathway is regulated in part by the Bcl2 family of proteins, all containing a BH3 domain. The proteins in the Bcl2 family go on to activate Bax-like proteins, which will
permeabilize the outer membrane of the mitochondria [72]. This releases the pro-apoptotic factors
such as cytochrome c into the cytoplasm. The released cytochrome c can then lead to the activation
of the initiator caspase-9 by binding Apoptosis Protease Activating Factor 1 (Apaf-1) and procaspase-9 to form the apoptosome [71]. Caspase-9 will set off a caspase cascade of subsequent
executioner caspase activations such as caspase-3, leading to the induction of apoptosis in the cell
[72]. The appearance of phosphotidylserine on the outer leaflet of apoptotic cells then facilitates
phagocytic recognition, allowing for their early uptake and disposal [73].
Intrinsic apoptosis is additionally able to follow a caspase-independent pathway. The
release of apoptosis-inducing factor (AIF) and endonuclease G (EndoG) from the inner
mitochondrial membrane space results in the degradation and fragmentation of DNA in cells
following apoptotic stimuli [74].
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In the extrinsic pathway (Figure 3), the signaling pathways that initiate apoptosis involve
transmembrane receptor-mediated interactions. These involve death receptors that are members of
the tumor necrosis factor (TNF) receptor gene superfamily [75]. In the FasL/FasR model of the
extrinsic pathway, when the ligand binds to the Fas receptor, this leads to the recruitment of the
adapter protein Fas-associated death domain (FADD), as well as the binding of TNF ligand to TNF
receptor. This results in the binding of the adapter protein TNF receptor type-1 associated death
domain (TRADD) with recruitment of FADD [76]. FADD will associate with procaspase-8 to
form the death-inducing signaling complex (DISC). This formation of DISC will set off a caspase
cascade, leading to apoptosis by the activation of initiator caspase-8 and caspase-10 through
adaptor proteins, namely FADD [72].
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Figure 3: The intrinsic and extrinsic pathways of apoptosis. The intrinsic pathway is found on the left,
while the extrinsic pathway is found on the right. Initiation factors will lead to the recruitment of pro-apoptotic
members of the Bcl2 family to the mitochondria, permeabilizing the membrane to allow for releasing of other
pro-apoptotic proteins such as cytochrome C. The activation of death receptors will then lead to the activation
of the extrinsic pathway The activation of both pathways leads to a caspase cascade eventually leading to
apoptosis (Zhang et al, 2016).
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1.5

Current Cancer Treatments
Current approaches to cancer treatment include chemotherapy, surgery, and radiation

therapy. Although effective, these treatment types may cause inadvertent side effects due to their
lack of selectivity for cancer cells and toxicity to normal healthy cells [77]. Chemotherapy-based
regimens seem to have reached a therapeutic plateau due to dosage limitations stemming from the
risk of fatal side effects [78]. Surgical removal of the tumour has been excellent in cases of early
detection, and substantial advances have been made to improve detection and diagnostics of
various cancers [79]. However, the effectiveness of this method is limited to cases in which the
tumour has not yet invaded or metastasized to other locations. It has also been established that
cancer relapse is common in patients undergoing surgery, with nearly 50% of cases having
recurrence within 3 years of surgery [80]. Radiation therapy has been implicated in genomic
instability after treatment, ultimately leading to further cancer development, due to their ability to
induce mutations in the genome that may lead to upregulation of oncogenes or inhibition of tumour
suppressor genes [81]. Thus, these treatments designed to destroy cancer cells may end up leading
to toxicity, eventual relapse, or further cancer development.
Once cancers have progressed to the metastatic stage, treatment approaches tend to focus
on the usage of chemotherapies to eradicate the primary tumour while fighting any secondary
metastases. Chemotherapies including DNA damaging therapeutics, e.g. cisplatin, doxorubicin, or
5-fluorouracil, and tubulin modifying agents, e.g. paclitaxel, have been developed to induce
apoptosis in cancer cells. However, many issues and limitations have arisen with these drugs due
to their non-selective nature and extreme toxicity to healthy tissues. Furthermore, cancer cells
develop resistance to these drugs and patients may end up experiencing severe side effects without
any effect on cancer [82-85]. In addition, these genotoxic treatments lead to DNA damage in
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normal tissues with increasing risk of cancer development. Thus, we are risking the use of cancerinducing compounds in our attempts to treat cancer.
Targeted Treatments
Due to lack of selectivity and potential toxicity in cancer treatments, it is critical to discover
and development targeted therapeutics that are able to induce selective cancer cell death. Of
particular interest in our research group is the targeting of cancer cell mitochondria and metabolism
due to their inherent differences as described in section 1.2. To exploit these vulnerabilities in
cancer cells, current advances have designed compounds capable of targeting these differences.
Of particular interest to our group was the ability of mitochondria-targeting agents able to induce
selective apoptosis (mitocans) to target the metabolism and oxidative stress defense mechanisms
of cancer.
Cancer cells rely heavily on aerobic glycolysis and, as a result, over-express hexokinases
(HK) which catalyze the first step of glucose metabolism [86]. Targeting hexokinase II (HKII) or
voltage-dependent anion channel 1 (VDAC1) can uncouple their interaction with each other,
potentially stunting aerobic glycolysis, leading to cancer cell death [87,88]. Current treatments
have not only selectively induced cell death cancer cells but have led to metabolic stimulation of
healthy cells [89-92].
An interesting approach to cancer treatment lies in engineering mitocans that are able to
target electron transport chain (ETC) complex proteins [93]. Treatments designed to target cancer
cell OxPhos may shut down an important machinery in cancer cell metabolism, sensitizing them
to aerobic glycolysis targeting agents or potentially facilitate to the leakage of mitochondrial proapoptotic proteins. Our group has previously demonstrated that pancrasitatin (PST) analogs
induced apoptosis at extremely low EC50 levels in a wide variety of cancers with a much higher
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efficacy than standard chemotherapeutics [94]. PST analogs were additionally shown to be
interacting with complex II or III in order to exert its anti-cancer effects. It may be possible that
PST analogs interact or bind with complex II or III in order to exploit an unidentified mechanism
of cancer cell metabolism, or potentially affect downstream pathways of these complexes.
Finally, increased oxidative stress can affect mitochondrial proteins leading to further
dysfunction of mitochondria, generating more ROS thus starting a vicious cycle of oxidative stress
and mitochondrial dysfunction. Thus, targeting mitochondria or oxidative stress defense
mechanisms can initiate this vicious cycle leading to cell death [95]. By generating excessive ROS,
cancer cell defense mechanisms may be unable to cope with increased oxidative stress leading to
apoptosis. Indeed, many recent studies have demonstrated selective apoptosis induction in cancer
cells [96-99].
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1.6

Natural Health Products
Natural health products (NHPs) are materials isolated from various food and plant sources

that have been shown to have medicinal properties [100]. In fact, many current therapies for a wide
variety of diseases originate from natural compounds. For example, the commonly used
chemotherapeutic taxol was isolated from the bark extract of the Pacific yew tree, Taxus brevifolia,
when the extract was shown to have a cytotoxic effect on cancer [101]. It is possible that welltolerated, highly potent anticancer compounds are still left to be discovered and developed into a
novel cancer therapeutics.
The traditional application of natural health products (NHPs) as medicinal products have
been documented throughout history in numerous applications – likely dating back thousands
of years before recorded history [102]. NHPs are compounds derived from natural sources such
as plants and thus must have been some of the first sources of medicinally active materials
available for traditional treatments and therapies [102]. The ancient Egyptian document Ebers
Papyru, dated around 1550 BC, contained 800 complex prescriptions and 700 natural agents
including Aloe vera (aloe), Boswellia carteri (frankincense) and the oil of Ricinus communis
(castor) [103]. Numerous natural products have been used by the Indian Ayurveda, a medical
system using natural products shown to have strong anti-inflammatory and medicinal properties
[104].
Continued investigation of NHPs has allowed for their identification as potential cancer
therapies due to their high efficacy and ability to be selective for cancer cells. This has led to
NHP and NHP derivatives to come to the forefront in research to find alternative approaches to
cancer treatment [105]. The anti-cancer activity of NHPs has been shown to be a result of multiple
bioactive compounds targeting various vulnerabilities of cancer cells, rather than the effects of
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one bioactive compound. These whole plant materials have been widely used for the extent of
recorded history, and placing a focus on whole plant extracts may allow for the development of
an efficacious treatment that is well-tolerated and may be taken for a long period of time to avoid
cancer relapse and improve the quality of life of diagnosed patients [105].
Recently there have been many advances in NHP efficacy on cancer. NHPs have been
shown to target many cancer cell mitochondrial vulnerabilities. Recent studies have shown that
NHP and NHP derivatives are able to selectively target cancer cell metabolism and induce cell
death [106-110]. Our own research on natural extracts of dandelion root [111], long pepper [112],
lemongrass and white tea [113] were shown to be highly effective in inducing apoptosis via the
generation of excessive ROS and dissipation of the MMP.
Currently, oncologists and clinicians rightfully do not recommend specific natural products
for general consumption alongside of chemotherapy treatments [114]. This is primarily due to the
risk of chemotherapy inhibition by NHPs that are known as powerful antioxidants, leading to
reduced efficacy in treatment [115]. Many clinicians encourage their patients to use proven
chemoprevention strategies to reduce their cancer risk due to the lack of solid scientific backing
the usage of NHPs in cancer treatment. Further, they encourage patients to enroll in regulated
clinical trials of NHPs to help build the sample data to potentially bring NHPs to market [114].
Thus, this thesis and recent NHP research in the last decade has focused on developing and
investigating NHP in a standard, reproducible, and unbiased manner to validate them as effective
anticancer agents.
Three NHPs have been studied for this thesis due to our previous experimental results
showing promise as anticancer agents. Taraxacum officinale, more commonly regarded as the
dandelion plant, has been used for centuries to treat absecesses, reduce inflammation, and treat
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gastrointestinal diseases [116]. Cymbopogon citratus, commonly known as lemongrass, has
traditionally been used to treat fever, inflammation, digestive disorders and cancer [117]. Hibiscus
rosa-sinesis, the hibiscus flower, has traditionally been used and has been shown to have high
pharmacological potential to treat disorders such as hypertension and pyrexia [118].
Dandelion Root
Preclinical research on dandelion has shown that dandelion root shows anti-inflammatory,
anti-angiogenic, and anti-neoplastic properties [119]. Further, dandelion root has been shown to
induce cytotoxicity due to its ability to induce oxidative stress, inflammation, and the secretion of
apoptotic factors to induce apoptosis [120-122]. Dandelion root and leaf extracts showed potent
radical scavenging and reducing activity [123]. Our research group has established the efficacy of
dandelion root extract (DRE) on leukemia and pancreatic cancer, but its effects on prostate cancer
has not yet been elucidated. Further, the interactions of DRE with common chemotherapeutics
have yet to be investigated to validate their usage as an adjuvant in cancer treatment.
Compounds extracted from dandelion root extract include caffeic and chlorogenic acids
along with vitexin-2-rhamnoside (apigenin). Further, hesperidin and myricetin were uniquely
detected in the crude powdered root extract while luteolin-7-O-glucoside and isovitexin were both
present in the leaf extract [123]. These compounds have been shown to be strong antioxidants
while having anti-inflammatory properties [124-126]. However, the specific anti-cancer effects of
these compounds have yet to be tested.
Lemongrass
Preclinical research on lemongrass has demonstrated the antiproliferative and antioxidative
abilities of lemongrass extract (LGE). LGE showed anticancer efficacy on colon, breast, and
ovarian cancer at very low EC50 concentrations ranging from 68 μg/mL to 104.6 μg/mL while
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having no significant effect on normal liver cells [127]. Lemongrass essential oils were shown to
suppress the proliferation and survival of lung cancer cells, additionally enhancing the anticancer
effect of chemotherapeutics [128]. Further, these oils showed antioxidative and anti-inflammatory
properties on prostate and glioblastoma cell lines [129].
Our research on lemongrass has substantiated LGE validity by showing their significant
anticancer efficacy on lymphoma using an in vitro and in vivo model [113]. Three compounds
identified at higher concentrations in lemongrass (elemicin, lonicerin, and methylisoeugenol)
showed very poor efficacy in reducing viability in lymphoma cells when treated individually. We
believe that this could potentially be due to the fact that multiple phytochemicals may work
together in natural extracts. Thus, the usage of whole plant extracts may allow for the targeting of
multiple vulnerabilities of cancer.
Hibiscus
Preclinical research has shown that hibiscus extract (HE) exhibits significant anticancer
efficacy on prostate cancer, leukemia, gastric cancer, and human squamous cell carcinoma [130133]. Extracts of hibiscus have shown antioxidant, cholesterol-lowering, anti-obesity, insulin
resistance reduction, anti-hypertensive, and skin cancer chemopreventative properties [134]. A
previous study of Hibiscus syriacus observed that several triterpenoids, including betulin and
betulinic acid, from HE inhibited triple-negative breast cancer cell viability with limited toxicity
on normal cells [135]. Aqueous HE has also been shown to inhibit melanoma growth in an in vitro
model [136]. In addition to botulin and betulinic acid, protocatechuic acid (PCA) has been shown
to demonstrate significant antiviral activity, but no work on cancer has been conducted [137].
Hibiscus has shown high promise as a therapeutic, and merits further investigation as an anticancer treatment option.
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1.7

Hypothesis, Objectives, Significance

Hypothesis
There is significance evidence supporting the importance of NHPs in drug development as
well-tolerated treatments for cancer. As well, there is a necessity for the scientific validation to
promote the usage of these NHPs alongside current treatment options in adjuvant therapy to
mitigate chemotherapy-related toxicity and improve patient prognosis. This research focused on
analyzing the anti-cancer efficacy of three NHPs, dandelion root extract (DRE), lemongrass extract
(LGE), and hibiscus extract (HE), on cancer as well as determining the drug-drug interactions of
these extracts.
Our hypothesis is that DRE, LGE, and HE are able to selectively target cancer cell
vulnerabilities to induce apoptosis in a selective manner, and will be able to enhance the
anticancer efficacy of chemotherapeutics when used in combination in cellular and animal models
of cancer.
Objectives
To study this hypothesis, three major objectives were identified:
1. Evaluation of the ability of DRE, LGE, and HE to induce selective cell death in several in
vitro and in vivo cancer models.
2. Evaluation of the adjuvant ability of DRE, LGE, and HE to enhance the anticancer efficacy
of common chemotherapeutics in in vitro and in vivo cancer models.
3. Investigation into the mechanisms of action of DRE, LGE, and HE in cancer cell models
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Significance
The collective burden of cancer and current cancer therapeutics indicate a critical need for
the development of treatments which are more effective, selective, and financially reasonable.
Many conventional cancer treatments are unable to selectively target cancer cells, and
unfortunately will induce apoptosis in non-cancerous healthy cells. The purpose of this study is to
develop NHPs as cancer therapeutics able to selectively induce apoptosis against cancer cells.
Many oncologists are rightfully hesitant to promote the usage of NHPs alongside
chemotherapeutics due to a lack of reproducible scientific validation. The scientific studies carried
out with DRE, LGE, and HE will provide evidence allowing for the introduction of these NHPs as
an efficacious anticancer therapy as well as a suitable treatment partner for many current
therapeutics. In doing so, we will be able to provide a safer and cheaper complementary treatment
for cancer to improve patient prognosis.
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2.1

Introduction
Prostate cancer remains one of the most commonly diagnosed cancers among men

worldwide, accounting for 1 in 5 new diagnoses [1]. Advances in prostate cancer detection
including improvement of prostate specific antigen detection methods [2], and functional MRI
techniques [3, 4] have resulted in reduced mortality rates due to early diagnosis and treatment of
the disease. However, prostate cancer related fatality is associated with late diagnoses, and
progression to the metastatic castration-resistant stage [5]. At this stage, common treatment
approaches involve chemotherapy treatment including first-line therapies such as mitoxantrone
and docetaxel [5].
Current treatments for prostate cancer have included chemotherapy, radiation therapy,
hormonal therapy, and cryosurgery among others [8]. Many chemotherapeutic treatment
approaches have been developed, targeting vulnerabilities in cancerous cells to induce
programmed cell death, also known as apoptosis [6, 7]. Unfortunately, although these treatments
have shown efficacy, many adverse side effects have been observed in patients undergoing these
treatments [8]. For example, cardiac toxicity has been observed in the usage of mitoxantrone
treatment [9, 10]. These side effects can be attributed to the nonspecific nature of the treatment for
cancer, resulting in the targeting of healthy noncancerous cells. However, aggressive metastatic
cancers pose a constant threat of relapse following remission by chemotherapy treatment.
Randomized phase 3 trials have shown that androgen deprivation therapy along with docetaxel
improved relapse-free survival in prostate cancer patients [11], the long-term usage of
chemotherapies is highly undesirable due to the inadvertent side effects. Thus, there is a great need
for the development of treatment approaches that can avoid treatment-related toxicity and able to
be used on a long-term basis.
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The potential of natural health products (NHPs) in cancer treatments presents an interesting
option that can be well-tolerated and could be used over a long period of time. NHPs are materials
that have been extracted from plant sources that have exhibited medicinal properties [12].
Interestingly, many of the current chemotherapeutic compounds have been isolated from plantbased materials, for example paclitaxel (otherwise known as taxol) from the Pacific yew tree
(Taxus brevifolia) bark extract [13]. It could be possible that there are plant extracts that are welltolerated, have selective toxicity for cancer cells, and target multiple vulnerabilities of cancer cells.
Our research into dandelion root, lemongrass, long pepper, and hibiscus extracts have shown that
these NHPs have the potential to induce apoptosis selectively in cancer cells [14-17]. These
extracts have also been used widely and traditionally as food or medicinal products [18]. Thus,
these extracts are well-tolerated and have the potential for long-term consumption to help prevent
cancer remission. Although we have conducted research on dandelion root extract and lemongrass
extract on colon cancer, leukemia, and lymphoma with high levels of success, their specific effect
on prostate cancer is yet to be investigated. Furthermore, the interaction of DRE and LGE with
standard cancer treatments has not yet been studied.
Dandelion (Taraxacum officinale) root has traditionally been used in Chinese, Arabian and
Native American traditional medicine for the purpose of treating diseases including digestive
ailments to cancers [19]. Lemongrass (Cymbopogon citratus) has also been used traditionally and
has been shown to anti-inflammatory, anti-microbial, and radical scavenging anti-oxidant
properties in many diseases [20-22]. As mentioned previously, both of these extracts have been
investigated in colon cancer, leukemia, and lymphoma cells, but their effect on prostate cancer
remain undetermined [14, 15, 17, 23]. Our objective was to investigate dandelion root extract
(DRE) and lemongrass extract (LGE) to assess their ability to induce apoptosis in prostate cancer
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cells in vitro and in vivo. More importantly, we wanted to assess the interaction of DRE and LGE
with current chemotherapies to assess their potential use in adjuvant therapies.
In this study, we have shown that aqueous dandelion root extract (DRE) and ethanolic
lemongrass extract (LGE) are able to induce apoptosis in prostate cancer in a dose and timedependent manner. Further, we have demonstrated that both treatments are selective for prostate
cancer with no significant effect on normal healthy cells. Importantly, we have shown for the first
time that DRE and LGE display positive interactions with current chemotherapeutic agents (i.e.
they are able to enhance the efficacy of chemotherapies) on prostate cancer. The efficacy of DRE
and LGE were further demonstrated in prostate cancer xenografts in immunocompromised mice,
showing a reduction of tumour burden by oral administration of DRE and LGE. These results
support the potential of DRE and LGE as viable alternatives to current treatments, as well as their
validity in adjuvant therapies. This in turn may lead to the development of a well-tolerated longterm treatment option.
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2.2

Materials and Methods

Dandelion root aqueous extraction and Lemongrass ethanolic extraction
Asian dandelion (Taraxacum officinale) root were obtained from Premier Herbal Inc.
(Toronto, ON, Canada). The flowers were grinded using a coffee grinder into a fine powder. The
powder was extracted in boiled double distilled water (ddH2O) (1 g leaf powder to 10 mL ddH2O)
at 60°C for 3 hours. The extract was then run through a cheese cloth and then filtered via gravity
filtration with a P8 coarse filter, followed by vacuum filtration with a 0.45 µm filter (PALL Life
Sciences, VWR, Mississauga ON Cat No. 28148-028). The water extract was frozen at -80˚C,
freeze dried using a lyophilizer and then reconstituted in ddH2O in order to obtain a final stock
concentration of 100 mg/mL. Prior to use, the water extract was passed through a 0.22 µm filter
(Sarstedt, Montreal, QC, CA Cat No. 83.1826.001) in a biosafety cabinet.
Lemongrass (Cymbopogon citratus) will obtained from Premier Herbal Inc. The
lemongrass was grinded using a coffee grinder into a fine powder. The powder was extracted in
100% anhydrous ethanol (1 g leaf powder to 10 mL anhydrous ethanol) at room temperature
overnight. The extract was filtered via gravity filtration with a P8 coarse filter, followed by vacuum
filtration with a 0.45 µm filter. The extract was evaporated using a RotoVap at 40°C and
reconstituted in ethanol to obtain a final stock concentration of 200 mg/ml. The ethanolic extract
was then passed through an Acrodisc® 0.2µm DMSO-safe syringe filter in a biosafety cabinet.
Cell culture
The prostate cancer cell line DU-145 (ATCC® HTB-81™) was cultured in Eagle's
Minimum Essential Medium (EMEM) (ATCC® 30-2003™) supplemented with 10% (v/v) fetal
bovine serum (FBS, Catalog No. 12484-020, Thermo Scientific, Waltham, MA, USA) and 0.4%
(v/v) gentamicin (Catalog No. 15710-064, Gibco BRL, VWR, Mississauga, ON, CA).
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The prostate cancer cell line PC-3 (ATCC® CRL-1435™) was cultured in F-12K Medium
(Kaighn's Modification of Ham's F-12 Medium) (ATCC® 30-2004™) supplemented with 10%
(v/v) fetal bovine serum (FBS) and 0.4% (v/v) gentamicin.
The normal colon mucosa cell line (ATCC® CRL-1831™) was cultured in Dulbecco's
Modified Eagle's Medium (DMEM) (ATCC® 30-2002™) supplemented with 10% (v/v) fetal
bovine serum (FBS) and 0.4% (v/v) gentamicin.
All cells were maintained in an incubator at 37ºC with 5% CO2 and 95% humidity. All
cells were passaged for less than 6 months.
Trypan Blue exclusion assay
Equal amounts of cells were seeded onto a 6-well clear bottom tissue culture plate and
treated with various concentrations of aqueous dandelion root extract and chemotherapeutics. 48and 96-hours post-treatment, cells were collected and washed with phosphate buffer saline (PBS).
Cells were then re-suspended in 100µL of PBS and an equal amount (100µL) of Trypan Blue
solution (Catalog No. T8154, Sigma-Aldrich, Mississauga, ON, CA). The number of viable cells
were counted using the Countess® II FL automated cell counter (Life Technologies, Burlington,
ON, CA). Results were analyzed using the GraphPad Prism 6 software and expressed as “Number
of viable cells/mL” and expressed over a growth curve of the number of viable cells over the
treatment period.
Analysis of cell death: Annexin V (AV) binding assay and propidium iodide (PI)
Annexin V binding assay and propidium iodide staining were performed to respectively
monitor early apoptosis and cell permeabilization, a marker of necrotic or late apoptotic cell death.
Cells were washed with phosphate buffer saline (PBS) and suspended in Annexin V binding buffer
(10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) with green fluorescent Annexin V

47

AlexaFluor-488 (1:20) (Life Technologies Inc, Cat. No. A13201, Burlington, ON, Canada) and
0.01 mg/mL of red fluorescent PI (Life Technologies Inc, Cat. No. P3566, Burlington, ON,
Canada) for 15 minutes at 37°C protected from light. Percentage of early (green), late apoptotic
cells (green and red), and necrotic cells (red) were quantified with a Tali Image-Based Cytometer
(Life Technologies Inc., Cat. No. T10796, Burlington, ON, Canada). Cells from at least 18 random
fields were analyzed using both the green (ex. 458 nm; em. 525/20 nm) and red (ex. 530 nm; em.
585 nm) channels. Fluorescent micrographs were taken at 400x magnification using LAS AF6000
software with a Leica DMI6000 fluorescent microscope (Wetzlar, Germany). Cells monitored with
microscopy were counterstained with Hoechst 33342 (Molecular Probes, Eugene, OR, USA) with
a final concentration of 10 μM during the 15-minute incubation.
Reactive oxygen species (ROS) scavenging
To assess the dependence on apoptotic induction on oxidative stress, the ROS scavenger
N-acetylcysteine (NAC) was used to rescue cells. Cells were pretreated with 10 μL NAC (SigmaAldrich Canada, Cat. No. A7250, Mississauga, ON, Canada) for 30 minutes at 37°C at 5% CO2.
Cells were then treated for the indicated durations, collected, washed with phosphate buffer saline
(PBS), and suspended in Annexin V binding buffer with green fluorescent Annexin V AlexaFluor488 (1:20) and 0.01 mg/mL of red fluorescent PI for 15 minutes at 37°C protected from light.
Percentage of early (green), late apoptotic cells (green and red), and necrotic cells (red) were
quantified with a Tali Image-Based Cytometer. Cells from at least 18 random fields were analyzed
using both the green (ex. 458 nm; em. 525/20 nm) and red (ex. 530 nm; em. 585 nm) channels.
Caspase inhibition
To assess the caspase dependence of apoptotic induction, the caspase inhibitor Z-VADFMK was used to rescue cells. Cells were pretreated with 4 μL Z-VAD-FMK (Sigma-Aldrich
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Canada, Cat. No. V116, Mississauga, ON, Canada) for 30 minutes at 37°C at 5% CO2. Cells were
then treated for the indicated durations, collected, washed with phosphate buffer saline (PBS), and
suspended in Annexin V binding buffer with green fluorescent Annexin V AlexaFluor-488 (1:20)
and 0.01 mg/mL of red fluorescent PI for 15 minutes at 37°C protected from light. Percentage of
early (green), late apoptotic cells (green and red), and necrotic cells (red) were quantified with a
Tali Image-Based Cytometer. Cells from at least 18 random fields were analyzed using both the
green (ex. 458 nm; em. 525/20 nm) and red (ex. 530 nm; em. 585 nm) channels.
In vivo assessment of the dandelion root and lemongrass extract efficacy
Immuno-compromised CD1 nu/nu mice, aged six weeks old, were obtained from Charles
River Laboratories. Mice were housed and the protocols were followed using relevant guidelines
and regulations that were approved by the University of Windsor Animal Care Committee (AUPP
#17-15) in accordance with the Canadian Animal Care committee in a laboratory setting with 12hour light/dark cycles. Following an acclimatization period, mice were injected subcutaneously
with prostate cancer cells (DU-145, PC-3) cell lines suspension in Matrigel® at a concentration of
1.0x106 cells per mouse in the hind flanks. Upon tumour formation, mice were randomly separated
into four groups (control, DRE drinking water, and LG drinking water). Control and
chemotherapeutic mice were given normal water, while DRE treatment groups received 40
mg/kg/day while LGE treatment groups received 16 mg/kg/day for 8 weeks. Mice were then
sacrificed using CO2 chamber followed by cervical dislocation, and tumours were harvested.
Tumour volumes (using the formula ½*(L*W2) to calculate approximate volume) and body
weights of each mouse were measured every other day throughout the length of the study.
Statistical Analysis
All statistical analysis was done using the GraphPad 6.0 Prism software. To test for
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statistical significance a two-way analysis of variance (ANOVA) was used. All trials were
conducted at least three independent times.
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2.3

Results

Dandelion root and lemongrass extracts induce apoptosis in a dose- and time-dependent
manner in prostate cancer cells
Hot water extract of dandelion root and ethanolic extract of lemongrass were prepared as
described in the materials and methods. To investigate the anti-cancer efficacy of dandelion root
extract (DRE) and lemongrass extract (LGE), prostate cancer cells were stained using Trypan Blue
dye to assess cell permeability via image-based cytometry following 48- and 96-hour treatments.
Prostate cancer cells (DU-145, PC-3) were additionally fluorescently stained with the apoptotic
markers Annexin V (AV) and propidium iodide (PI). The cells were then subjected to fluorescent
image-based cytometry following 48- and 96-hour treatments.
LGE was observed to be effective at inducing cell death through the Trypan Exclusion
assay while DRE showed efficacy only at 96-hour treatment (Figure 1A). These observations were
corroborated by fluorescence image cytometry results indicating that LGE and DRE are effective
in inducing apoptosis as early as 48-hours and 96-hours post-treatment, respectively (Figure 1B).
Specifically, significant apoptosis was observed in both prostate cancer cell lines for LGE
beginning at dosages of 0.05 mg/mL (0.05 mg of crude extract in 1 mL of DMSO) at both
timepoints. For DRE, significant apoptosis induction was observed beginning at 4 mg/mL
treatments. Dosage and time dependent apoptosis induction was further observed in both cell lines
as increased treatment concentration and treatment times increased apoptotic induction.
Both prostate cancer cell lines were further treated with taxol in order to compare the
induction of apoptosis between standard chemotherapeutic treatment of taxol and DRE/LGE
treatment. In both cell lines, DRE and LGE treatments resulted in comparable or enhanced
apoptotic induction when compared to taxol treatment (Figure 1B).
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Figure 1: Dandelion root and lemongrass extracts induce apoptosis in prostate cancer cells. (A) Prostate cell line DU145 was treated with various treatments of dandelion root extract (DRE), lemongrass extract (LGE), and chemotherapeutics
taxol and mitoxantrone and assessed at 48 hours and 96 hours. Results were obtained using image-based cytometry to assess
the percentage of live cells compared to a vehicle control. (B) Prostate cell lines DU-145 (top panels) and PC-3 (bottom
panels) were treated with various treatments of DRE, LGE, and chemotherapeutics and assessed at 48 hours and 96 hours.
Results were obtained using image-based cytometry to assess the percentage of cells positive with fluorescence associated
with Annexin V (green), propidium iodide (PI, red), both (yellow), or negative for both Annexin V and PI (blue). Values are
expressed as a mean ± SD from three independent experiments. Statistical calculations were performed using Two-Way
ANOVA multiple comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control.
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Dandelion root extract and lemongrass extract are selective for prostate cancer cells
If DRE and LGE treatments are selective for prostate cancer, the risk of drug-related side
effects could be minimized. To assess whether DRE and LGE affects normal healthy noncancerous cells, normal colon mucosa (NCM-460) cells were treated with DRE and LGE and
assessed using fluorescent image-based cytometry as described above. Compared to an untreated
control, DRE and LGE treatments showed no significant increase in apoptotic induction (Figure
2). The highest dosages used in this experiment (4 mg/mL DRE, 0.05 mg/mL LGE) were able to
induce significant apoptosis when used to treat prostate cancer cells, but not NCM-460 cells.
Further, while DRE and LGE treatments showed no effect on normal healthy cells, taxol induced
apoptosis on these cells in a similar manner as on prostate cancer cells.
To further investigate the benefit of combinatorial treatments of DRE and LGE, the effect
of DRE or LGE addition to chemotherapy treatment on NCM-460 cells was investigated. If
protective, DRE or LGE would be able to minimize the amount of apoptotic induction on normal
healthy cells by taxol. Indeed, we have observed that the addition of DRE and LGE to standard
taxol chemotherapeutic treatment reduced the induction of apoptosis when compared to taxol
treatment alone (Figure 2). These results indicate that DRE and LGE are selective for prostate
cancer and can potentially protect normal healthy cells from being targeted by chemotherapy.
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Figure 2: Dandelion root and lemongrass extracts are selective for cancer and reduce toxicity of chemotherapeutics.
Normal colon mucosa (NCM-460) cells were treated with various dosages of dandelion root extract (DRE), lemongrass
extract (LGE) and DRE or LGE combination treatments with taxol and assessed at 48 hours. Results were obtained using
image-based cytometry to assess the percentage of cells positive with fluorescence associated with Annexin V (green),
propidium iodide (PI, red), both (yellow), or negative for both Annexin V and PI (blue). Values are expressed as a mean ±
SD from three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple
comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control, @p<0.05 vs. Individual
Chemotherapy Treatment.

Interactions of dandelion root and lemongrass extracts with standard chemotherapies taxol
and mitoxantrone
In standard treatments today, many chemotherapies are utilized in conjunction with other
drugs. To properly assess the potential of DRE and LGE to be used in adjuvant or combination
therapies in a novel treatment regimen, combination treatment assays were conducted to determine
the interactions between DRE or LGE with taxol and mitoxantrone. These NHPs may either
enhance, inhibit, or not affect chemotherapy efficacy. DU-145 prostate cancer cells were treated
with taxol or mitoxantrone in the presence or absence of 4 mg/mL DRE (Figure 3) or 0.01 mg/mL
LGE (Figure 4). As described in the materials and methods, both image-based cytometry and
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fluorescence microscopy were used to analyze the ability of these treatments to induce apoptosis
in prostate cancer cells.
The addition of 4 mg/mL DRE to mitoxantrone treatments was able to significantly
increase the induction of apoptosis when compared to mitoxantrone treatment alone (Figure 3A).
However, DRE did not seem to have any interaction with taxol and did not inhibit its action. The
addition of 0.01 mg/mL LGE to both taxol and mitoxantrone treatments were able to significantly
increase apoptosis induction compared to individual treatments (Figure 4A). Interestingly, the
lowest combination dosage of taxol treatment (0.01 μM with 0.01 mg/mL lemongrass extract)
showed comparable induction of apoptosis to the highest individual treatment dosage of taxol (0.5
μM). This indicates that LGE combination treatment was able to show a similar apoptosis
induction to individual treatment with a 50-fold decrease in chemotherapeutic concentration.
Morphological assays were conducted to assess the effect of treatments on cell
morphology. Fluorescent microscopy following Annexin V and propidium iodide staining after
combination DRE treatments (Figure 3B) and combination LGE treatments at 48 hours (Figure
4B) confirmed apoptosis induction as described above. These apoptotic markers were observed in
treated prostate cancer cells as expected, along with apoptotic morphology including cell
shrinkage, membrane blebbing, and nuclear condensation.
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Figure 3: Dandelion root extract enhances chemotherapeutic anti-cancer efficacy when treated in combination on
prostate cancer cells. (A) DU-145 cells were treated with chemotherapeutics taxol (top panel) and mitoxantrone (bottom
panel) individually and in combination with 4 mg/mL dandelion root extract (DRE) and assessed at 48 hours. Results were
obtained using image-based cytometry to assess the percentage of cells positive with fluorescence associated with Annexin
V (green), propidium iodide (PI, red), both (yellow), or negative for both Annexin V and PI (blue). Values are expressed as
a mean ± SD from three independent experiments. The percentage of viable cells were graphed for both individual
chemotherapeutic and combination chemotherapeutic treatments (graphs on right). (B) Fluorescence microscopy images of
individual and DRE combination chemotherapeutic treatments. Top panels: Brightfield and fluorescent merged images at
400x magnification. Bottom: Fluorescent images stained with Annexin V (green), PI (red), and Hoechst (blue) at 400×
magnification. Scale bar is 50 microns. Images are representative of three independent experiments. Statistical calculations
were performed using Two-Way ANOVA multiple comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p <
0.0001 vs. Control, @p<0.05 vs. Individual Chemotherapy Treatment.
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Figure 4: Lemongrass extract enhances chemotherapeutic anti-cancer efficacy when treated in combination on
prostate cancer cells. (A) DU-145 cells were treated with chemotherapeutics taxol (top panel) and mitoxantrone (bottom
panel) individually and in combination with 0.01 mg/mL lemongrass extract (LGE) and assessed at 48 hours. Results were
obtained using image-based cytometry to assess the percentage of cells positive with fluorescence associated with Annexin
V (green), propidium iodide (PI, red), both (yellow), or negative for both Annexin V and PI (blue). Values are expressed as
a mean ± SD from three independent experiments. The percentage of viable cells were graphed for both individual
chemotherapeutic and combination chemotherapeutic treatments (graphs on right). (B) Fluorescence microscopy images of
individual and LGE combination chemotherapeutic treatments. Top panels: Brightfield and fluorescent merged images at
400x magnification. Bottom: Fluorescent images stained with Annexin V (green), PI (red), and Hoechst (blue) at 400×
magnification. Scale bar is 50 microns. Images are representative of three independent experiments. Statistical calculations
were performed using Two-Way ANOVA multiple comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p <
0.0001 vs. Control, @p<0.05 vs. Individual Chemotherapy Treatment.
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Dandelion root extract-induced apoptosis is caspase-dependent, whereas lemongrass extractinduced apoptosis is dependent on oxidative stress
DRE and LGE are extracts composed of a wide variety of compounds that can interact and
function in complex manners. In order to further understand how these complex extracts exhibit
their anti-cancer effects, the mechanism of apoptotic induction should be investigated. In order to
determine if apoptosis is induced through oxidative stress, N-acetylcysteine (NAC) is used. NAC
is a reactive oxygen species (ROS) scavenger and thus is able to rescue cells from apoptosis if the
induction is primarily due to oxidative stress. LGE treatments on prostate cancer cells along with
NAC were able to significantly reduce the amount of apoptosis induction when compared to
individual LGE treatment whereas DRE treatments appear unaffected (Figure 5).
Further, to determine if apoptotic induction is caspase dependent or independent, Z-VADFMK, a commonly used broad-range caspase inhibitor, is used. If dependent, Z-VAD-FMK would
be able to rescue cells and indicate dependence as described above. Indeed, DRE treatments were
rescued when treating with DRE and Z-VAD-FMK, showing significant reduction of apoptotic
induction when compared to individual DRE treatment (Figure 5). LGE treatments did not respond
to caspase inhibition.
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Figure 5: Dandelion root extract apoptosis induction is caspase dependent and lemongrass extract apoptotic induction
is oxidative stress dependent. DU-145 cells were pre-treated with either N-acetylcysteine (NAC, reactive oxygen species
scavenger) or Z-VAD-FMK (caspase inhibitor), treated with various dosages of dandelion root extract (DRE), lemongrass
extract (LGE) and DRE or LGE combination treatments with taxol, and assessed at 48- and 96-hours. Results were obtained
using image-based cytometry to assess the percentage of cells positive with fluorescence associated with Annexin V (green),
propidium iodide (PI, red), both (yellow), or negative for both Annexin V and PI (blue). Values are expressed as a mean ±
SD from three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple
comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control, #p<0.05 vs. Individual DRE
Treatment, @p<0.05 vs. Individual LGE Treatment.

Oral administration of dandelion root and lemongrass extracts reduce the tumour burden
in prostate cancer xenograft models in immunocompromised mice
To confirm and further support the anti-cancer efficacy of DRE and LGE, we wanted to
investigate if these extracts have the ability to inhibit the growth of prostate cancer cells
xenografted in immunocompromised mice. DU-145 and PC-3 cells were transplanted
subcutaneously in mice. After tumour establishment, treatment groups were orally administered
either DRE or LGE supplemented drinking water for eight weeks. Indeed, DRE and LGE were
able to reduce the tumour burden of the xenografted mice as determined by tumour volume and
weight compared to vehicle controls (Figure 6A-B). Over the course of treatment, there was no
apparent change in the mice body weight gain in each treatment group when compared to controls,
indicating that these treatments were well tolerated (Figure 6C). Thus, DRE and LGE were
effective and well-tolerated in reducing tumour burden and growth in vivo when administered
orally.
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Figure 6: Dandelion root and lemongrass extracts administered orally reduce the tumour burden on prostate cancer
xenograft mice. DU-145 (A) and PC-3 (B) prostate cancer cells were xenografted onto immunocompromised mice hind
flanks subcutaneously. After tumour formation, these mice were orally fed dandelion root (DRE) and lemongrass (LGE)
extract for 8 weeks. After mice were sacrificed, tumours (top panels) were excised and measured for tumour volume (using
the formula ½*(L*W2) to calculate approximate volume) and tumour weight. (C) Mouse body mass was measured two times
a week and averaged to compare between control, DRE, and LGE groups. Statistical calculations were performed using OneWay ANOVA multiple comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control. No markings
indicate non-significance vs. Control.
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2.4

Discussion and Conclusions
We have demonstrated in this report that dandelion root extract (DRE) and lemongrass

extract (LGE) induce cell death in prostate cancer cells in a time and dosage dependent manner
(Figure 1). In contrast to chemotherapeutics like taxol, apoptosis induction by these extracts is
very selective for prostate cancer cells without any significant effect on normal colon mucosa
(NCM-460) (Figure 2). Importantly, we have shown that adjuvant treatment with DRE and LGE
in combination with taxol or mitoxantrone enhanced the apoptosis induction capacities of these
drugs (Figure 3, 4). Furthermore, we have evaluated the anti-cancer efficacy of both DRE and LGE
in vivo where we have shown that these extracts were able to significantly and drastically reduce
the tumour burden in mice with human prostate cancer xenografts.

These extracts were

administered orally, were well-tolerated, and did not affect mouse appetite or weight. These results
support the potential of DRE and LGE supplementation in chemotherapeutic regimens due to
observed enhancement of activity.
Previous work on DRE has shown its efficacy in inducing cell death in leukemia and colon
cancer cells [14, 17]. However, the effects of DRE and LGE on human prostate cancer cells
remained to be studied. Indeed, both DRE and LGE induced apoptosis in the two prostate cancer
cell lines in a time- and dose-dependent manner. These cells displayed characteristic features of
apoptosis including Annexin V binding. These extracts have been prepared using either water or
ethanol, both being biocompatible solvents thus they fall in the category of food supplements.
They have been traditionally consumed as teas or medicinal foods and have shown to be welltolerated. Although the dosages for DRE and LGE appear higher compared to pure compound
treatments used in therapeutics, it is important to note that these are crude extracts of dandelion
root and lemongrass. These extracts may contain many common compounds (salts and sugars) in
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addition to bioactive phytochemicals responsible for anti-cancer activity. We have previously
shown through phytochemical analysis on extracts of dandelion root, lemongrass, and long pepper
(Piper longum) that the active compound concentration is very low [14-16]. Further, we have
shown that the active components of DRE and long pepper extract were ineffective in inducing
apoptosis when used alone [16] indicating that these extracts may be effective through multiple
compounds working together and targeting multiple pathways.
Generally, oncologists are cautious in advising the usage of natural health products (NHPs)
alongside chemotherapies. This is primarily due to the potential of NHPs to interact negatively
with chemotherapeutic treatment, reducing the efficacy of these drugs. Therefore, it is extremely
important to investigate the interaction of these extracts with standard chemotherapeutics. We
investigated these interactions between DRE, LGE, and common chemotherapeutics. Indeed, we
have demonstrated that addition of 4 mg/mL DRE enhanced the efficacy of mitoxantrone while
not significantly affecting taxol (Figure 3). Further, addition of 0.01 mg/mL LGE was able to
enhance the efficacy of both taxol and mitoxantrone treatments (Figure 4). These results clearly
indicate that the interaction that these NHPs have with chemotherapeutics are positive, enhancing
the effect of chemotherapy. Most interestingly, addition of DRE to 1 nM mitoxantrone treatment
indicated similar apoptotic induction at a concentration of 20 nM mitoxantrone alone. Similarly,
addition of LGE to 0.01 μM taxol resulted in effects similar to 0.5 μM taxol. These results indicate
that adjuvant therapy with DRE and LGE could potentially reduce the concentration required, thus
avoiding drug-related adverse side-effects. Thus, we have shown for the first time that these NHPs
can be used as adjuvants to chemotherapies and potentially enhance their effect. Natural extracts
have been used in patients on chemotherapies to enhance their quality of life in some cases [24].
The mechanism of apoptosis induction by these extracts in prostate cancer is a topic of
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great interest to determine the underlying cause of cell death. We have previously demonstrated
that DRE and LGE were able to induce oxidative stress and decrease mitochondrial membrane
potential, leading to apoptosis induction in cancer cells [14, 15]. Though the exact mechanism is
not fully elucidated, it has been hypothesized that high reactive oxygen species (ROS) levels can
activate cellular stress mechanisms and may sensitize cancer cells to further ROS production
leading to apoptosis [25]. N-acetylcysteine (NAC), a known ROS scavenger, is able rescue cells
by inhibiting apoptosis induction via oxidative stress [26]. Further, we can use the caspase inhibitor
Z-VAD-FMK in order to assess the dependency of apoptosis induction on caspase action in a
similar manner. This assay allows for the assessment of whether our treatments are ROSdependent or caspase-dependent to induce apoptosis. Indeed, we have observed that LGE
treatment along with NAC was able to rescue DU-145 cells (Figure 5) while LGE treatment with
Z-VAD-FMK did not inhibit apoptosis, indicating that LGE treatment is ROS-dependent and
caspase-independent. Interestingly, DRE treatment did not show any inhibition by NAC but was
inhibited by Z-VAD-FMK, indicating that DRE treatment is caspase-dependent and ROSindependent. It is important to note that while these treatments showed some reduction, no cells
were completely rescued, indicating that the mechanism of action of these extracts may be multifaceted and should be further investigated. Further work could look into quantifying the amount
of ROS being produced via 2′, 7′-dicholorofluorescin diacetate (H2DCFDA) treatment or assessing
different mechanisms of action to further assess these extracts.
As indicated previously, taxol and mitoxantrone have shown inadvertent side-effects due
to the non-selective targeting [9, 10, 27]. Indeed, we observed that taxol was toxic to normal colon
mucosa (NCM-460) cells (Figure 2). We have shown in this study that LGE and DRE treatments
were selectively toxic to prostate cancer cells without affecting normal non-cancerous cells (Figure
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2). Interestingly, addition of DRE or LGE to taxol was able to significantly reduce the extent of
apoptosis in normal healthy cells compared to taxol treatment alone. This protective effect
indicates the potential for DRE and LGE use in long-term adjuvant therapy in order to reduce the
drug-related toxicity often associated with chemotherapy.
Some crude natural extracts have been shown to have anti-cancer efficacy against prostate
cancer, but these studies were limited to in vitro work [28-30]. It is very important to assess the
efficacy of natural extracts against prostate cancer using in vivo mice models with human prostate
cancer xenografts. We carried out in vivo studies in which the mice (with human prostate cancer
xenografts) were given DRE and LGE orally in their drinking water after tumour establishment.
Indeed, both DRE and LGE were able to reduce the tumour burden of prostate cancer tumours
significantly (Figure 6A-B) while having minimal effect on the overall weight gain of the mice
(Figure 6C) indicating general tolerance. These results indicated that the anti-cancer bioactive
compounds in these extracts must have been absorbed and stable upon systematic consumption
and eventually affecting the tumour growth on subcutaneous site. This is important as we must
consider that treatment was administered orally through mouse drinking water as opposed to
methods such as intravenous or intraperitoneal administration. We have already demonstrated that
both DRE and LGE are well-tolerated in mouse models [14, 15]. Thus, due to the fact that DRE
and LGE treatment were efficacious against prostate cancer and well-tolerated, these NHPs are
safe for long-term consumption prolonging the remission period.
Conclusions
In this study, we have demonstrated the efficacy of DRE and LGE for inducing cell death
selectively in prostate cancer cells. For the first time, we have shown positive interactions of DRE
and LGE with standard chemotherapeutics like taxol and mitoxantrone as they enhance their ability
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to induce apoptosis. Most importantly, addition of DRE and LGE led to reduced dosages of
chemotherapies with same extent of apoptosis compared to individual treatments (at high doses).
Thus, DRE and LGE can reduce the drug-related toxicity with chemotherapeutics by reducing the
dosage required for treatment. Further, oral administration of DRE and LGE to mice with human
prostate cancer xenografts was able to significantly reduce the tumour burden. These extracts were
well-tolerated in these mice as indicated by normal weight gain and food intake. Thus, these results
suggest that DRE and LGE could potentially be used alongside mitoxantrone and taxol as
adjuvants to enhance the efficacy of these drugs as well as improve the quality of life due to
reduced toxicity for prostate cancer patients. These findings also provide support for the further
development of these NHPs as a promising anticancer option to treating prostate cancer.
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3.1

Introduction
Breast cancer is the most prevalent cancer among women worldwide, accounting for 25%

of cancer incidence and 15% of cancer deaths among females [1]. Current work has developed and
enhanced prediction models, screening methods, diagnostic tools, and disease management [2-6].
However, breast cancer treatment approaches become more complicated once the disease
progresses to the complex metastatic stage. Although surgery to remove tumours in breast cancer
has a high probability of survival, the majority of breast cancer related deaths are not from the
primary tumour itself, but a result of metastasis to organs [7].
Apoptosis is the complex and ordered physiological process of cell death. An
understanding of cell death, particularly in relation to cancer, allows for an assessment of the
pathogenesis and treatment of the disease [8]. The exploitation of cellular vulnerabilities in
cancerous cells, including oxidative stress and mitochondrial membrane destabilization, by
therapeutic agents could trigger apoptosis and potentially eradicate the disease [9,10]. Indeed, most
therapeutics have been developed to induce cell death. However, many treatments are
unfortunately nonspecific for cancer and can additionally target healthy non-cancerous cells
eventually leading to inadvertent side effects and toxicity [11,12].
Current treatments for metastatic breast cancer include adjuvant chemotherapy using
cytotoxic drugs including anthracyclines, taxane-based, and platinum-based drugs [13]. Although
both taxane-based and platinum-based chemotherapeutics have shown effectiveness in treating
breast cancer, both drugs have exhibited toxicity and lack of selectivity to support a long-term
treatment plan [11,12]. One study evaluating over 1000 patients found that treatments of
anthracycline and taxane-based adjuvant strategies led to a higher pathologic complete response
and higher survivability. However, a high risk of tumour relapse is possible if the tumour is not
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completely eradicated [14,15]. Thus, there exists a great need for a treatment that can avoid toxicity
in treatments while also able to be used on a long-term basis.
Natural health products (NHPs) are materials isolated from various food and plant sources
that have been shown to have medicinal properties [16]. The commonly used chemotherapeutic
taxol was isolated from the bark extract of the Pacific yew tree, Taxus brevifolia, when the extract
was shown to have a cytotoxic effect [17]. Although many treatments have been derived from
natural sources, we have yet to exhaust nature’s vast variety of selection. It is possible that a welltolerated, highly potent anticancer compound is still left to be discovered and developed into a
novel cancer therapeutic. Indeed, many NHPs have been shown to induce apoptosis selectively in
cancer cells, including our research into dandelion root, lemongrass, and long pepper extracts [1820]. Traditionally, NHPs have been used widely as both medicinal and food products [21].
Hibiscus flower (Hibiscus rosa-sinesis) has traditionally been used and has been shown to
have high pharmacological potential to treat disorders such as hypertension and pyrexia [22].
Further, hibiscus extract (HE) has been shown to have significant antioxidant and hypolipidemic
effects [23]. Previous work on hibiscus has indicated that HE exhibits significant anticancer
efficacy on prostate cancer, leukemia, gastric cancer, and human squamous cell carcinoma [2427]. A previous study of Hibiscus syriacus observed that several triterpenoids from HE were able
to inhibit triple-negative breast cancer cell viability with limited toxicity on normal cells [28]. This
work lends support to the notion that a whole plant extract of hibiscus could contain anticancer
compounds while being well-tolerated.
Triple-negative breast cancer accounts for approximately 15-20% of all breast cancers and
is characterized by negative expression of estrogen and progesterone receptors as well as HER2
protein [29]. Many challenges arise in the treatment of triple-negative breast cancer due to poor
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prognosis resulting from the lack of actionable targets in order to use a specific targeted therapy
able to combat the disease [30,31]. As such, the discovery and development of therapies able to
target triple-negative breast cancer is of great importance.
We aimed to investigate the efficacy of HE against breast cancer by assessing the toxicity
of HE treatment on human triple-negative and estrogen-receptor positive (ER+) breast cancer cells.
Further, we aimed to investigate its interaction with current chemotherapies to assess the potential
of its use in adjuvant therapies.
In this study, we have shown that aqueous HE is able to induce apoptosis in breast cancer
cell models in vitro in a dose-dependent manner. We have also shown that HE treatment shows
selectivity for cancer cells, with minimal effect on normal non-cancerous cells. Most importantly,
we wanted to investigate the potential of using HE as an adjuvant to current chemotherapeutic
treatments. We have demonstrated HE treatments (when combined with chemotherapeutic
treatments) enhanced the induction of apoptosis when compared to individual treatment alone.
These results support the possibility of supplementing chemotherapeutic regimens with HE, which
has shown to be well-tolerated in normal non-cancerous cells. This may lead to a better combined
effect, reducing the chemotherapeutic dosages and related toxicity.
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3.2

Materials and Methods

Hibiscus leaf aqueous extraction
Hibiscus flower (Hibiscus rosa-sinensis) were obtained from Premier Herbal Inc. (Toronto,
ON, Canada). This aqueous extraction protocol is similar to that previously published with the
following modifications [18,19]. The flowers were grinded using a coffee grinder into a fine
powder. The powder was extracted in boiled double distilled water (ddH2O) (1 g leaf powder to
10 mL ddH2O) at 60°C for 3 hours. The extract was then run through a cheese cloth and then
filtered via gravity filtration with a P8 coarse filter, followed by vacuum filtration with a 0.45 µm
filter (PALL Life Sciences, VWR, Mississauga ON, CA Cat No. 28148-028). The water extract
was frozen at -80˚C, freeze dried using a lyophilizer and then reconstituted in ddH2O in order to
obtain a final stock concentration of 100 mg/mL. Prior to use, the water extract was passed through
a 0.22 µm filter (Sarstedt, Montreal, QC, CA Cat No. 83.1826.001) in a biosafety cabinet.
Cell Culture
The breast cancer cell line MCF-7 (ATCC® HTB-22™) were cultured in Dulbecco's
Modified Eagle's Medium (DMEM) (ATCC® 30-2002™) supplemented with 10% (v/v) fetal
bovine serum (FBS, Thermo Scientific, Waltham, MA, USA, Cat No. 12484-020) and 0.4% (v/v)
gentamicin

(Gibco

BRL,

VWR,

Mississauga,

ON,

CA

Cat No. 15710-064).
The breast cancer cell line MDA-MB-231 (ATCC® HTB-26™) were cultured in Eagle's
Minimum Essential Medium (EMEM) (ATCC® 30-2003™) supplemented with 10% (v/v) fetal
bovine serum (FBS) and 0.4% (v/v) gentamicin.
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The normal human skin fibroblast cell line (NHF; Coriell Institute for Medical Research,
Cat. No. AG09309, Camden, NJ, USA) were cultured in Eagle's Minimum Essential Medium
(EMEM) (ATCC® 30-2003™) supplemented with 10% (v/v) fetal bovine serum (FBS) and 0.4%
(v/v) gentamicin.
All cells were maintained in an incubator at 37ºC with 5% CO2 and 95% humidity. All
cells were cultured for less than 6 months with regular passaging.
Analysis of cell death: annexin V binding assay and propidium iodide
Annexin V binding assay and propidium iodide staining were performed to respectively
monitor early apoptosis and cell permeabilization, a marker of necrotic or late apoptotic cell death.
Cells were treated with various concentrations of hibiscus flower extract similar to those published
previously with aqueous extracts of dandelion root and white tea [18,19]. Cells were then treated
individually or in combination with chemotherapeutics taxol, cisplatin, and tamoxifen as indicated
in the results section. This protocol is similar to that previously published [18,19]. Cells were
washed with phosphate-buffered saline (PBS) and suspended in Annexin V binding buffer (10 mM
HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) with green fluorescent Annexin V AlexaFluor488 (1:20) (Life Technologies Inc, Burlington, ON, CA, Cat No. A13201) and 0.01 mg/mL of red
fluorescent PI (Life Technologies Inc, Burlington, ON, CA, Cat No. P3566) for 15 minutes at 37°C
protected from light. Percentage of early (green), late apoptotic cells (green and red), and necrotic
cells (red) were quantified with a Tali Image-Based Cytometer (Life Technologies Inc, Burlington,
ON, CA, Cat No. T10796). Cells from at least 18 random fields were analyzed using both the green
(ex. 458 nm; em. 525/20 nm) and red (ex. 530 nm; em. 585 nm) channels. Fluorescent micrographs
were taken at 400x magnification using LAS AF6000 software with a Leica DMI6000 fluorescent
microscope (Wetzlar, Germany). Cells monitored with microscopy were counterstained with
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Hoechst 33342 (Molecular Probes, Eugene, OR, USA) with a final concentration of 10 μM during
the 15-minute incubation.
Reactive oxygen species (ROS) quantification
Whole cell ROS generation was monitored with the small molecule 2′, 7′dicholorofluorescin diacetate (H2DCFDA). H2DCFDA enters the cell and is deacetylated by
esterases and oxidized by ROS to the highly fluorescent 2′, 7′-dicholorofluorescein (DCF)
(excitation 495 nm; emission 529 nm). This protocol is similar to that previously published [18,19].
Cells were pretreated with 20 μM H2DCFDA (Sigma-Aldrich Canada, Cat. No. D6883,
Mississauga, ON, Canada) for 30 minutes at 37°C protected from light at 5% CO2. Cells were
treated for the indicated durations, collected, centrifuged at 3500 × g for 5 minutes, and
resuspended in PBS. Percentage of DCF positive cells was quantified using the Tali Image-Based
Cytometer (Life Technologies Inc, Burlington, ON, CA, Cat No. T10796) using 13 random fields
per group with the green channel (excitation 458 nm; emission 525/20 nm). Cells were monitored
with microscopy and counterstained with Hoechst 33342. Images were taken with a Leica
DMI6000 fluorescent microscope (Wetzlar, Germany) at 400x magnification using LAS AF6000
software.
Mitochondrial potential monitoring
Tetramethylrhodamine methyl ester (TMRM) (Gibco BRL, VWR, Mississauga, ON, CA,
Cat No. 89139-392) was used for detecting mitochondrial membrane potential (MMP), an
indicator of healthy intact mitochondria. This protocol is similar to that previously published
[18,19]. Following incubation with TMRM, cells were collected, washed with 1x PBS,
resuspended in PBS, and then analyzed using the Tali Image-Based Cytometer (Life Technologies
Inc, Burlington, ON, CA, Cat No. T10796). Cells from 13 random fields were analyzed using the
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red (ex. 530 nm; em. 585 nm) channel. Cells were monitored with microscopy and counterstained
with Hoechst 33342. Images were taken with a Leica DMI6000 fluorescent microscope (Wetzlar,
Germany) at 400x magnification using LAS AF6000 software.
Statistical Analysis
All statistical analysis was done using the GraphPad 6.0 Prism software. To test for
statistical significance a two-way analysis of variance (ANOVA) was used. All trials were
conducted at least three independent times.
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3.3

Results

Hibiscus extract induces apoptosis in a dosage dependent manner in triple-negative and
estrogen-receptor positive breast cancer cells
Hot water extract of hibiscus flower was prepared as described in the material and methods.
To assess the ability of HE to induce apoptosis in breast cancer, triple-negative and ER+ breast
cancer cells were fluorescently stained with apoptosis markers Annexin V (AV) and propidium
iodide (PI). The cells were subjected to fluorescent image-based cytometry and fluorescent
microscopy following 48- and 96-hour treatments.
HE was effective in inducing apoptosis in both triple-negative MDA-MB-231 and ER+
MCF-7 breast cancer cells (Figure 1A). Specifically, significant apoptosis induction was observed
in both breast cancer cell lines at a dosage of 2 mg/mL (2 mg of crude lyophilized extract in 1 mL
of ddH2O). Dosage dependent apoptosis induction was observed in both cell lines as increasing
treatment concentration increased the amount of apoptosis observed.
Both MDA-MB-231 and MCF-7 cells were additionally treated with tamoxifen, taxol, and
cisplatin to compare the induction of apoptosis between standard chemotherapeutic treatments and
HE. In both cell lines, tamoxifen and cisplatin treatments did not significantly induce apoptosis
and taxol significantly induced apoptosis only in MDA-MB-231 cells (Figure 1A). HE treatment
at 4 mg/mL caused significant induction of apoptosis at a comparable or greater level to all
chemotherapeutics tested.
Morphological assays were conducted to assess the effect of treatments on cell
morphology. Fluorescent microscopy using AV and PI after hibiscus treatments at 48 hours
confirmed apoptosis induction due to hibiscus. These apoptosis markers were observed in MDA-
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MB-231 breast cancer cells as expected, along with apoptotic morphology including cell
shrinkage, membrane blebbing, and nuclear condensation (Figure 1B).

Figure 1: Hibiscus extracts induce apoptosis in breast cancer. (A) Breast cancer cell lines MDA-MB-231 and MCF-7
were treated with various treatments of HE and chemotherapeutics and assessed at 48 hours and 96 hours. Results were
obtained using image-based cytometry to assess the percentage of cells positive with fluorescence associated with Annexin
V (green), PI (red), both (yellow), or negative for both Annexin V and PI (blue). Values are expressed as a mean ± SD from
three independent experiments. (B) Fluorescence microscopy images of 1.0, 4.0 and 5.0 mg/mL HE treatment on MDAMB-231 cells were taken at 48 hours. Top panels: Brightfield and fluorescent merged images at 400x magnification. Bottom:
Fluorescent images stained with Annexin V (green), PI (red), and Hoechst (blue) at 400× magnification. Scale bar is 50
microns. Images are representative of three independent experiments. Statistical calculations were performed using TwoWay ANOVA multiple comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control.
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Interaction of hibiscus extract with conventional chemotherapies tamoxifen, taxol, and
cisplatin in combination treatments
Commonly today, many chemotherapeutics are utilized in conjunction with other drugs. In
order to assess if HE can be combined with chemotherapeutics in a novel treatment regimen,
combination assays were conducted to determine whether or not hibiscus enhances, inhibits, or
has no effect on chemotherapeutic potency. MDA-MB-231 and MCF-7 breast cancer cells were
treated with tamoxifen, taxol, and cisplatin in the presence or absence 1 mg/mL HE. As described
above, both image-based cytometry and fluorescent microscopy were used to analyze apoptosis
induction.
In the triple-negative breast cancer cell line, MDA-MB-231, combination treatments of
chemotherapeutics taxol and cisplatin with 1 mg/mL HE were able to significantly increase the
induction of apoptosis when compared to chemotherapeutic treatments alone (Figure 2A).
Interestingly, the lowest combination concentration of taxol treatment (0.01 μM with 1 mg/mL
HE) showed similar apoptosis induction to the highest individual treatment concentration of taxol
(0.5 μM). This indicates that combination treatment with 1 mg/mL HE was able to show a similar
apoptosis induction to individual treatment with a 50-fold decrease in chemotherapeutic
concentration. Using fluorescent microscopy, this result was confirmed with combination
treatments of taxol and cisplatin along with HE showing a higher incidence of apoptotic marker
fluorescence and increased apoptotic morphology when compared to individual chemotherapeutic
treatments (Figure 2B).
In ER+ breast cancer cell line, MCF-7, combination treatments of chemotherapeutics
tamoxifen, taxol and cisplatin with 1 mg/mL HE did not show any significant change in apoptosis
induction when compared to individual treatments (Figure 3A). Although we did not observe any
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enhancement, there was no inhibition observed. This result was confirmed using fluorescent
microscopy (Figure 3B). However, it is important to note that the chemotherapeutic treatment
ranges used did not show any significant apoptosis induction in MCF-7. As shown in Figure 1, HE
at a concentration of 2 mg/mL showed significant apoptosis induction while combination
treatments with 1 mg/mL did not induce significant apoptosis.
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Figure 2: Hibiscus extracts indicate synergy with chemotherapeutics when treated in combination on triple-negative
breast cancer cells. (A) MDA-MB-231 cells were treated with chemotherapeutics taxol (top panel) and cisplatin (bottom
panel) individually and in combination with 1 mg/mL HE and assessed at 48 hours. Results were obtained using imagebased cytometry to assess the percentage of cells positive with fluorescence associated with Annexin V (green), PI (red),
both (yellow), or negative for both Annexin V and PI (blue). Values are expressed as a mean ± SD from three independent
experiments. The percentage of viable cells were graphed for both individual chemotherapeutic and combination
chemotherapeutic treatments (graphs on right). (B) Fluorescence microscopy images of individual and hibiscus combination
chemotherapeutic treatments on MDA-MB-231 cells were taken at 48 hours. Top panels: Brightfield and fluorescent merged
images at 400x magnification. Bottom: Fluorescent images stained with Annexin V (green), PI (red), and Hoechst (blue) at
400× magnification. Scale bar is 50 microns. Images are representative of three independent experiments. Statistical
calculations were performed using Two-Way ANOVA multiple comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control,
****p < 0.0001 vs. Control, @p<0.05 vs. Individual Chemotherapy Treatment.
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Figure 3: Hibiscus extracts do not interact with chemotherapeutics in combination treatment on estrogen-receptor
positive breast cancer. (A) MCF-7 cells were treated with chemotherapeutics tamoxifen (top panel, taxol (middle panel),
and cisplatin (bottom panel) individually and in combination with 1 mg/mL HE and assessed at 48 hours. Results were
obtained using image-based cytometry to assess the percentage of cells positive with fluorescence associated with Annexin
V (green), PI (red), both (yellow), or negative for both Annexin V and PI (blue). Values are expressed as a mean ± SD from
three independent experiments. The percentage of viable cells were graphed for both individual chemotherapeutic and
combination chemotherapeutic treatments (graphs on right). (B) Fluorescence microscopy images of individual and hibiscus
combination chemotherapeutic treatments on MDA-MB-231 cells were taken at 48 hours. Top panels: Brightfield and
fluorescent merged images at 400x magnification. Bottom: Fluorescent images stained with Annexin V (green), PI (red),
and Hoechst (blue) at 400× magnification. Scale bar is 50 microns. Images are representative of three independent
experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison. *p < 0.05 vs. Control,
**p < 0.01 vs. Control, ****p < 0.0001 vs. Control, @p<0.05 vs. Individual Chemotherapy Treatment, # = not significant
vs. Individual Chemotherapy Treatment.
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Hibiscus extract is selective in inducing apoptosis for breast cancer cells
If selective for breast cancer, individual and combinatory HE treatment could potentially
minimize adverse side effects by not affecting healthy cells. In order to investigate the selectivity
of HE for breast cancer, normal human fibroblast (NHF) cells were treated with HE treatments
and assessed in a similar manner as described above. Compared to control treatments, there was
no increase in apoptosis in HE up to 2 mg/mL at which we have observed significant apoptosis in
cancer cells (Figure 1). There was minimal to no observable apoptosis induction when compared
to the positive control taxol (at a high dosage known to be cytotoxic to normal human cells) using
HE treatments that were highly efficacious when used to treat breast cancer cells (Figure 4A).
These results were confirmed with fluorescent microscopy. Cells only began to show apoptotic
marker fluorescence and apoptotic morphology at the highest HE concentration of 5 mg/mL
(Figure 4C).
To further investigate the benefit of using a combination treatment of HE with
chemotherapeutics, taxol and hibiscus combination treatments were compared to individual
treatments of taxol on NHF cells. On their own, chemotherapeutics treatments showed toxicity
(Figure 4B). They are non-selective compared to hibiscus. Most surprisingly, HE combination
treatments did not lead to increased apoptosis induction when compared to individual treatments,
but instead lowered the amount of apoptosis induction observed (Figure 4B). These results indicate
that HE shows selectivity to breast cancer cells and potentially protects normal human healthy
cells from being affected by chemotherapeutic treatments.

84

Figure 4: Hibiscus extracts are selective for cancer and reduce toxicity of chemotherapeutics. (A) NHF cells were
treated with various dosages of HE and (B) hibiscus combination treatments with taxol and assessed at 48 hours. Results
were obtained using image-based cytometry to assess the percentage of cells positive with fluorescence associated with
Annexin V (green), PI (red), both (yellow), or negative for both Annexin V and PI (blue). Values are expressed as a mean ±
SD from three independent experiments. The percentage of viable cells were graphed for both individual chemotherapeutic
and combination chemotherapeutic treatments (graphs on right). (C) Fluorescence microscopy images of individual hibiscus
treatments on NHF cells were taken at 48 hours. Top panels: Brightfield and fluorescent merged images at 400x
magnification. Bottom: Fluorescent images stained with Annexin V (green), PI (red), and Hoechst (blue) at 400×
magnification. Scale bar is 50 microns. Images are representative of three independent experiments. Statistical calculations
were performed using Two-Way ANOVA multiple comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p <
0.0001 vs. Control, @p<0.05 vs. Individual Chemotherapy Treatment.
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Hibiscus extract is able to induce apoptosis in breast cancer cells by increasing oxidative
stress and targeting the mitochondria
HE is an extract composed of many compounds able to interact in a complex manner.
Determining the method of apoptosis induction will allow for a greater understanding of how these
complex extracts show the observed anticancer potency. In order to determine if HE is able to
induce apoptosis in breast cancer through inducing oxidative stress, H2DCFDA was used to
monitor the generation of ROS in breast cancer cells treated with chemotherapeutics in the
presence or absence of HE. Indeed, it was observed that individual HE treatment was able to induce
significant ROS generation in treated cells (Figure 5A). Further, combination treatments on triplenegative MDA-MB-231 cells using chemotherapeutic and HE were able to significantly increase
the generation of ROS in treated cells when compared to treatment in the absence of HE. These
results were confirmed using fluorescence microscopy (Figure 5B).
Further, as HE is made up of multiple factors and components, some of these may also
target the mitochondria. Tetramethylrhodamine methyl ester (TMRM) dye was used in order to
visualize the mitochondria membrane potential (MMP) in treated cells. Interestingly, HE at 1
mg/mL did not show significant loss of the MMP but instead was able to amplify the loss of MMP
in both triple-negative and ER+ breast cancer cells when present in chemotherapeutic treatment
compared to when absent (Figure 6A). These results were confirmed using fluorescent microscopy
(Figure 6B).
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Figure 5: Hibiscus extract induces oxidative stress on breast cancer and enhances chemotherapeutic oxidative stress
induction. (A) MDA-MB-231 (left) MCF-7 (right) breast cancer cells were treated with chemotherapeutics taxol and
cisplatin individually and in combination with 1 mg/mL HE and assessed at 3 hours post-treatment against a positive control
of hydrogen peroxide (H2O2). Results were obtained using image-based cytometry to assess the percentage of cells positive
with fluorescence associated with the generation of reactive oxygen species (H2DCFDA, fluoresces green). Values are
expressed as a mean ± SD from three independent experiments. (B) Fluorescence microscopy images of individual and
hibiscus combination chemotherapeutic treatments on MDA-MB-231 and MCF-7 cells were taken at 3 hours.. Left image
in groupings: Fluorescent images stained with H2DCFDA (green) and Hoechst (blue) at 400× magnification. Right image in
groupings: Fluorescent images stained with H2DCFDA (green) alone. Images are representative of three independent
experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison. *p < 0.05 vs. Control,
**p < 0.01 vs. Control, ****p < 0.0001 vs. Control, @p<0.05 vs. Individual Chemotherapy Treatment.
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Figure 6: Hibiscus extract enhances chemotherapeutic ability to reduce mitochondrial membrane potential. (A)
MDA-MB-231 (left) MCF-7 (right) breast cancer cells were treated with chemotherapeutics taxol and cisplatin individually
and in combination with 1 mg/mL HE and assessed at 48 hours. Results were obtained using image-based cytometry to
assess the percentage of cells positive with fluorescence associated with mitochondrial membrane potential (TMRM,
fluoresces red). Values are expressed as a mean ± SD from three independent experiments. (B) Fluorescence microscopy
images of individual and hibiscus combination chemotherapeutic treatments on MDA-MB-231 and MCF-7 cells were taken
at 48 hours. Fluorescent images stained with TMRM (red) and Hoechst (blue) at 400× magnification. Images are
representative of three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple
comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control, @p<0.05 vs. Individual
Chemotherapy Treatment.
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3.4

Discussion and Conclusions
In this study, we have shown that HE is able to induce apoptosis in both human ER+ and

triple-negative breast cancer cell lines in vitro (Figure 2A). We have demonstrated that HE
treatment is very selective in inducing cell death in cancer cells without any significant effect on
NHF cells (Figure 4A). On the other hand, common chemotherapeutics like taxol were
indiscriminate and induced apoptosis in both cancer and non-cancerous cells (Figure 4A). Most
importantly, we have shown that addition of HE in combination with chemotherapeutic agents
enhanced the induction of apoptosis in triple-negative breast cancer cells (Figure 2A). These
results support the possibility of supplementing chemotherapeutic regimens with HE, which is
well-tolerated in normal healthy cells. This may lead to a better combined effect, reducing the
chemotherapeutic dosages needed in treatment and therefore reduce toxicity.
As indicated previously, breast cancer, primarily triple-negative, is highly resistant to
chemotherapy treatment. We have shown that both triple-negative and ER-positive breast cancer
cells are affected by HE treatment (Figure 2). HE has also been shown to induce apoptosis
significantly around treatment of 2 mg/mL of crude extract in prostate cancer, with a similar dosedependency [24].
A common hesitation of using natural health product extracts alongside chemotherapies is
the possibility of negative drug interactions, leading to reduced efficacy in treatment. Our goal was
to investigate whether or not combination HE treatments would inhibit, not affect, or enhance the
efficacy of chemotherapeutic treatments. Indeed, we found that taxol and cisplatin treatments on
triple-negative breast cancer cells were enhanced with the addition of 1 mg/mL (sublethal dosage
in individual treatment) HE treatment (Figure 2) while unaffected in ER-positive breast cancer
cells. These results clearly indicate that HE’s interaction with chemotherapeutic drugs is positive
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or has no interaction in breast cancer cells. If any effect was observed at all, HE treatment enhanced
the efficacy of chemotherapeutic treatments. Moreover, HE combination treatments on NHF cells
were able to reduce the toxicity of taxol (Figure 4A). Extent of apoptosis induced by 0.01 μM taxol
in combination with HE was equivalent to that induced by 0.5 μM taxol alone (Figure 2A). This
50-fold decrease in effective chemotherapy concentration clearly indicates the possibility of
reducing chemotherapeutic dosage to avoid adverse side-effects without sacrificing efficacy. As
such, HE could serve a significant purpose in terms of adjuvant therapy.
The mechanism of apoptosis induction in breast cancer is a topic of great interest to
determine the underlying cause of cell death. Previously, we have shown that ethanolic extracts of
lemongrass and aqueous extracts of dandelion root were able to induce oxidative stress and
decrease mitochondrial membrane potential, leading to apoptosis induction in cancer cells [18,19].
While the exact mechanism is not yet clear, it has been hypothesized that high ROS levels can
activate cellular stress mechanisms and may sensitize cancer cells to further ROS production
leading to apoptosis [9]. Indeed, our results indicate that HE treatment led to increased ROS
generation in both triple-negative and ER+ breast cancer cells (Figure 5). Moreover, taxol and
cisplatin treatments in combination with HE showed increased ROS generation when compared to
individual treatments. This helps explain the increase in apoptosis induction of combination
treatments compared to individual treatments as discussed above (Figure 3, 4). It should be noted
that triple-negative breast cancer cells were more vulnerable to oxidative stress than ER-positive
breast cancer cells. These are two different cells with varied susceptibilities, and the lowered ROS
generation of ER-positive breast cancer treatment indicates either an alternate mechanism of
apoptosis induction or a need for increased dosage. Further, we have demonstrated that HE
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combination treatment is able to enhance the mitochondrial membrane potential reduction in breast
cancer cells (Figure 6).
As indicated above, cisplatin and taxol have shown extremely toxic side effects due to a
lack of selectivity in treatment. Studies have indicated that HE is well-tolerated in nude mice
xenograft models while exhibiting an anti-metastatic and anti-tumour effect [24]. Hibiscus has
been traditionally used and has shown to be well-tolerated when consumed by humans.
Consumption has also been associated with many beneficial effects including supporting
mitochondrial function, energy homeostasis and improvement of the cardiovascular health [32].
Indeed, we have shown that HE was selectively toxic to cancer cells wherein the lowest effective
dose of HE on breast cancer (2 mg/mL) was unable affect NHF cells (Figure 4A). HE treatments
in combination with chemotherapeutics were also able to reduce the toxicity in NHF cells and
lower the amount of apoptosis induction when compared to chemotherapeutic treatments in the
absence of HE (Figure 4B). As such, HE shows great potential as an adjuvant to these therapies
and help render some selectivity in treatment for cancer. If HE treatment shows anticancer efficacy,
it could be used over a long-term period of time without any side effects [33].
It is important to note that HE dosages may appear to be high compared to pure compound
cancer therapeutics. However, it is important to note that this is an aqueous extract of the hibiscus
flower, which contains mainly sugars, salts, and other naturally abundant compounds in flowers.
Previous work on phytochemical analysis of many other extracts including long pepper (Piper
longum) and dandelion root (Taraxacum officinale) have shown that the concentration of the active
compound might be very low [18,20]. Further, our work on these NHPs showed that active
compounds found in long pepper and dandelion root extract were ineffective in apoptosis induction
when used alone [20]. This indicates the importance of multiple phytochemicals that work together
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natural extracts. In this case, it represents a very interesting opportunity for further research into
HE to identify and test the potency of active compounds in aqueous hibiscus flower extract.
Conclusions
The work presented in this study indicates great potential of NHPs such HE to treat breast
cancer in combination with standard chemotherapies. HE has shown an ability to enhance
apoptotic induction by chemotherapy treatments through an increase in ROS generation and
mitochondrial membrane collapse on both triple-negative and ER-positive breast cancer cells. This
result is significant due to the general difficulty in discovery of an effective treatment for resistant
triple-negative breast cancer. Most importantly, addition of HE with chemotherapeutic treatment
could produce desired level of apoptotic induction at very low dosages of chemotherapies
compared to chemotherapies alone. Therefore, addition of HE can significantly reduce the drugrelated toxicity of chemotherapeutics. Future work into assessment of HE can look into
combinatorial effects on in vivo models to further investigate the potential of HE for human usage.
We have shown that HE treatment has the potential to be used alongside tamoxifen, taxol, and
cisplatin treatments without any inhibition of drug potency. Thus, these findings open up
interesting opportunity for further development of NHPs as a promising anticancer treatment
option.
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Chapter 4
Lemongrass (Cymbopogon citratus) effectively induces apoptosis in
colon cancer cells and interacts with FOLFOX in vitro and in vivo

Manuscript currently in preparation for submission by Christopher Nguyen, Ivan Ruvinov, and
Ben Scaria.
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4.1

Introduction
Colorectal cancer (CRC) is the second most commonly diagnosed cancer in Canada,

comprising 13% of all cases in 2018. It is estimated that 1 in 13 men and 1 in 16 women in Canada
will develop CRC during his or her lifetime, and of those, 28% and 19% respectively are expected
to die [1]. Thus, it is critical that we develop more accurate diagnostic methods, better-researched
preventative measures, and most importantly, safer treatment plans.
Chemotherapy cancer treatment consists of the usage of chemical agents able to halt the
growth of tumors and potentially reduce their size. They can be used alone or in combination with
other therapies such as surgery and radiation, however their therapeutic usage is nonselective and
leads to toxicity in healthy noncancer cells. They often target characteristics of cells which are not
unique to cancerous cells, thus additionally affecting healthy cells and resulting in serious side
effects to patients [2]. The most common chemotherapy treatment for CRC is a combination of
fluorouracil (5-FU), folinic acid (LV), and oxaliplatin, otherwise collectively known as FOLFOX.
Although it is generally successful, this treatment does have toxic side effects including
gastrointestinal and neuro-toxicities [3]. Due to the potential for further patient risk due to adverse
side effects, it is advisable to develop selective treatments able to target cancer cells and induce
cell death.
Natural health products (NHPs) have been used traditionally for their medicinal properties
and wide applications. Although their usage has been recorded over thousands of years, they often
lack scientific credibility and experimental validation and are thus overlooked by medical
professionals when prescribing treatments. Regardless, many chemically synthetic drugs have
derived from plants or are analogous to compounds found in plants [4]. Due to their relatively
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inexpensive cost and abundancy, researchers are now shifting their attention to development of
NHPs as well-tolerated and effective treatments for cancer.
Health care professionals are often hesitant to allow patients undergoing cancer treatments
to experiment with NHPs due to the possibility that they might interfere with the anticancer effects
of the chemotherapy agents. However, it has been reported that increases in oxidative stress may
interfere with chemotherapeutic efficacy in inducing apoptosis in cancer cells [5]. Indeed, previous
studies involving the treatment of cancers using NHPs have shown underlying mechanisms
involving increases in reactive oxygen species (ROS) production [6,7]. It is therefore vital to
conduct a scientifically sound evaluation of the drug-drug interactions between different
treatments before medical professionals can comfortably allow NHP intake alongside
chemotherapy treatments.
Herein, we report lemongrass extract’s ability to induce apoptosis in CRC in vitro in colon
cancer cell lines and in vivo in colon cancer tumour xenograft mice models. LG was able to not
only effectively cause cancer cell death on its own, but also enhance the anticancer effects of two
standard chemotherapy drugs when administered in combination. These results also translated into
an animal study wherein oral administration of lemongrass extract was able to drastically reduce
tumor growth of xenografted mice alone and in combination with FOLFOX. More importantly,
lemongrass extract treatments proved to be non-toxic to normal colon cells in cell culture and to
the mice in the animal study.
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4.2

Materials and Methods

Lemongrass extraction
Lemongrass (Cymbopogon citratus) will obtained from Premier Herbal Inc. The
lemongrass was grinded using a coffee grinder into a fine powder. The powder was extracted in
100% anhydrous ethanol (1 g leaf powder to 10 mL anhydrous ethanol) at room temperature
overnight. The extract was filtered via gravity filtration with a P8 coarse filter, followed by vacuum
filtration with a 0.45 µm filter. The extract was evaporated using a RotoVap at 40°C and
reconstituted in ethanol to obtain a final stock concentration of 200 mg/ml. The ethanolic extract
was then passed through an Acrodisc® 0.2µm DMSO-safe syringe filter in a biosafety cabinet.
Cell Culture
The colon cancer cell line HT-29 (ATCC® HTB-38™) were cultured in McCoy’s 5A
Medium (ATCC® 30-2007™) supplemented with 10% (v/v) fetal bovine serum (FBS, Thermo
Scientific, Waltham, MA, USA, Cat No. 12484-020) and 0.4% (v/v) gentamicin (Gibco BRL,
VWR,

Mississauga,

ON,

CA

Cat No. 15710-064).
The colon cancer cell line HCT116 (ATCC® CCL-247™) were cultured in McCoy’s 5A
Medium supplemented with 10% (v/v) fetal bovine serum (FBS) and 0.4% (v/v) gentamicin.
The normal colon mucosa cell line (ATCC® CRL-1831™) was cultured in Dulbecco's Modified
Eagle's Medium (DMEM) (ATCC® 30-2002™) supplemented with 10% (v/v) fetal bovine serum
(FBS) and 0.4% (v/v) gentamicin.
The normal colon mucosa cell line NCM-460 (ATCC® CRL-1831™) was cultured in
Dulbecco's Modified Eagle's Medium (DMEM) (ATCC® 30-2002™) supplemented with 10%
(v/v) fetal bovine serum (FBS) and 0.4% (v/v) gentamicin.
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All cells were maintained in an incubator at 37ºC with 5% CO2 and 95% humidity. All
cells were cultured for less than 6 months with regular passaging.
Analysis of cell death: annexin V binding assay and propidium iodide
Annexin V binding assay and propidium iodide staining were performed to respectively
monitor early apoptosis and cell permeabilization, a marker of necrotic or late apoptotic cell death.
Cells were then treated individually or in combination with chemotherapeutics FOLFOX and taxol
as indicated in the results section. Cells were washed with phosphate-buffered saline (PBS) and
suspended in Annexin V binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4)
with green fluorescent Annexin V AlexaFluor-488 (1:20) (Life Technologies Inc, Burlington, ON,
CA, Cat No. A13201) and 0.01 mg/mL of red fluorescent PI (Life Technologies Inc, Burlington,
ON, CA, Cat No. P3566) for 15 minutes at 37°C protected from light. Percentage of early (green),
late apoptotic cells (green and red), and necrotic cells (red) were quantified with a Tali ImageBased Cytometer (Life Technologies Inc, Burlington, ON, CA, Cat No. T10796). Cells from at
least 18 random fields were analyzed using both the green (ex. 458 nm; em. 525/20 nm) and red
(ex. 530 nm; em. 585 nm) channels. Fluorescent micrographs were taken at 400x magnification
using LAS AF6000 software with a Leica DMI6000 fluorescent microscope (Wetzlar, Germany).
Cells monitored with microscopy were counterstained with Hoechst 33342 (Molecular Probes,
Eugene, OR, USA) with a final concentration of 10 μM during the 15-minute incubation.
Reactive oxygen species (ROS) quantification
Whole cell ROS generation was monitored with the small molecule 2′, 7′dicholorofluorescin diacetate (H2DCFDA). H2DCFDA enters the cell and is deacetylated by
esterases and oxidized by ROS to the highly fluorescent 2′, 7′-dicholorofluorescein (DCF)
(excitation 495 nm; emission 529 nm). Cells were pretreated with 20 μM H2DCFDA (Sigma-
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Aldrich Canada, Cat. No. D6883, Mississauga, ON, Canada) for 30 minutes at 37°C protected
from light at 5% CO2. Cells were treated for the indicated durations, collected, centrifuged at 3500
× g for 5 minutes, and resuspended in PBS. Percentage of DCF positive cells was quantified using
the Tali Image-Based Cytometer (Life Technologies Inc, Burlington, ON, CA, Cat No. T10796)
using 13 random fields per group with the green channel (excitation 458 nm; emission 525/20 nm).
Cells were monitored with microscopy and counterstained with Hoechst 33342. Images were taken
with a Leica DMI6000 fluorescent microscope (Wetzlar, Germany) at 400x magnification using
LAS AF6000 software.
Mitochondrial potential monitoring
Tetramethylrhodamine methyl ester (TMRM) (Gibco BRL, VWR, Mississauga, ON, CA,
Cat No. 89139-392) was used for detecting mitochondrial membrane potential (MMP), an
indicator of healthy intact mitochondria. Following incubation with TMRM, cells were collected,
washed with 1x PBS, resuspended in PBS, and then analyzed using the Tali Image-Based
Cytometer (Life Technologies Inc, Burlington, ON, CA, Cat No. T10796). Cells from 13 random
fields were analyzed using the red (ex. 530 nm; em. 585 nm) channel. Cells were monitored with
microscopy and counterstained with Hoechst 33342. Images were taken with a Leica DMI6000
fluorescent microscope (Wetzlar, Germany) at 400x magnification using LAS AF6000 software.
In vivo assessment of lemongrass extract efficacy and combinations with FOLFOX
Immuno-compromised CD1 nu/nu mice, aged six weeks old, were obtained from Charles
River Laboratories. Mice were housed and the protocols were followed using relevant guidelines
and regulations that were approved by the University of Windsor Animal Care Committee (AUPP
#17-15) in accordance with the Canadian Animal Care committee in a laboratory setting with 12hour light/dark cycles. Following an acclimatization period, mice were injected subcutaneously
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with colon cancer cells (HT-29, HCT 116) cell lines suspension in Matrigel® at a concentration
of 1.0x106 cells per mouse in the hind flanks. Upon tumour formation, mice were randomly
separated into four groups (control, LG drinking water, FOLFOX subcutaneous injection, LG
drinking water and FOLFOX subcutaneous injection). Control and chemotherapeutic mice were
given normal water, while LGE treatment groups received 16 mg/kg/day for 8 weeks. At 4 weeks,
subcutaneous injections of FOLFOX commenced once per week for 4 weeks. Mice were then
sacrificed using CO2 chamber followed by cervical dislocation, and tumours were harvested.
Tumour volumes (using the formula ½*(L*W2) to calculate approximate volume) and body
weights of each mouse were measured throughout the length of the study once per week.
Statistical Analysis
All statistical analysis was done using the GraphPad 6.0 Prism software. To test for
statistical significance a two-way analysis of variance (ANOVA) was used. All trials were
conducted at least three independent times.
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4.3

Results

Lemongrass extract displays anti-cancer activity in colon cancer and does so in a dosedependent manner in HCT116 cell line.
We assessed the ability of lemongrass extract (LGE) to induce apoptosis in two colon
cancer cell models at 48 hours post-treatment. Cells were treated with varying doses of LGE and
assessed for apoptotic activity using annexin V (AV) binding, which detects the externalization of
phosphatidylserine. Propidium iodide (PI) was simultaneously used to detect necrotic cells given
its ability to intercalate DNA, indicating cell permeabilization and death. Cells positive for AV
only (green) were considered to be early apoptotic cells, necrotic cells were detected as positive
for PI only. Those positive for both AV and PI reflected late apoptotic cells. Finally, those negative
for both AV and PI were considered as viable cells (Figure 1).
LGE was able to induce apoptosis in both CRC model cell lines at a 48-hour treatment time
point. It displayed dose-dependent anticancer activity in the less-aggressive HCT116 cell line but
was still able to significantly reduce cell viability in p53(-/-) HT-29 cell line. Staurosporine (STS)
was used as a positive control for its ability to induce apoptosis [8].
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Figure 1: Lemongrass extract induces apoptosis in colorectal cancer cells. Colon cell lines HCT 116 and HT-29 was
treated with various treatments of lemongrass (LG) extract and compared to a positive control of staurosporin at 48 hours.
Results were obtained using image-based cytometry to assess the percentage of live cells compared to a vehicle control.
Results were obtained using image-based cytometry to assess the percentage of cells positive with fluorescence associated
with Annexin V (green), propidium iodide (PI, red), both (yellow), or negative for both Annexin V and PI (blue). Values are
expressed as a mean ± SD from three independent experiments. Statistical calculations were performed using Two-Way
ANOVA multiple comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control.
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Lemongrass extract is non-toxic in a non-cancerous colorectal cell line.
We assessed the ability of LGE to selectively kill cells using a normal colon cell model.
Cells were treated with LGE at varying doses and monitored for the induction of apoptosis and
necrosis using image-based cytometry for AV binding and PI staining (Figure 2). 48-hours after
treatment, LGE displayed no significant apoptotic activity in normal colon (NCM-460) cell line.

Figure 2: Lemongrass extract is selective for cancer. Normal colon mucosa (NCM-460) cells were treated with various
dosages of lemongrass (LG) extract with staurosporin and assessed at 48 hours. Results were obtained using image-based
cytometry to assess the percentage of cells positive with fluorescence associated with Annexin V (green), propidium iodide
(PI, red), both (yellow), or negative for both Annexin V and PI (blue). Values are expressed as a mean ± SD from three
independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison. ns = not
significant, *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control.
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Lemongrass extract induces apoptosis in a time-dependent manner and does not inhibit the
anticancer activity of standard chemotherapies FOLFOX and taxol.
On its own, lemongrass extract was able to induce apoptosis in colon cancer cell lines at
very low doses. We next wanted to investigate whether treatment with LGE in combination with
synthetic chemotherapeutic drugs would have any effect on cell apoptosis of colon cancer cell
lines. Additionally, we wanted to observe whether these results would vary if the treatments are
left for a longer period of time before results are obtained.
To determine whether LGE interacts with standard chemotherapeutic drugs to either
enhance or reduce their effect, cells were treated with LGE alone and in combination with
FOLFOX and taxol and monitored for the induction of apoptosis using AV binding and PI staining
after 48 hours with image-based cytometry (Figure 3). No significant changes were observed
between the individual taxol and combinatorial treatments involving lemongrass extract and
standard chemotherapy drugs in HCT 116 cell line. However, FOLFOX apoptotic induction was
enhanced when used in combination with LGE compared to FOLFOX treatment alone. In the more
aggressive HT-29 cell line, a slight increase in cell apoptosis occurred when the treatments were
used in combination, however not large enough to conclusively deem significant.
Cells were also observed with these identical agents at a later time point to observe the
time-dependent effects of the treatments. Once treated, this batch of cells was monitored for the
induction of apoptosis after 96 hours with image-based cytometry (Figure 3). Results showed the
same pattern as the 48-hour trial where combination treatments in the HCT 116 cell line showed
no increase or decrease in cell apoptosis whereas combination treatments in the HT-29 cell line
only slightly enhanced cell death relative to the individual treatments. However, a slightly greater
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proportion of cells from both cell lines indicated to be undergoing apoptosis at 96 hours compared
to their 48-hour counterpart treatments.

Figure 3: Lemongrass extracts do not inhibit chemotherapeutic efficacy when treated in combination on colorectal
cancer cells. HCT 116 and HT-29 cells were treated with chemotherapeutics FOLFOX and taxol individually and in
combination with 0.025 mg/mL lemongrass extract and assessed at 48 hours and 96 hours. Results were obtained using
image-based cytometry to assess the percentage of cells positive with fluorescence associated with Annexin V (green), PI
(red), both (yellow), or negative for both Annexin V and PI (blue). Values are expressed as a mean ± SD from three
independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison. *p < 0.05
vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control, @p<0.05 vs. Individual Chemotherapy Treatment.
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Changes in morphology and characterization of apoptosis following treatment with
lemongrass extract alone and in combination with chemotherapeutics.
Qualitative analysis of HCT 116 and HT-29 cells was performed to complement
quantitative results of combination treatments. Cells were incubated with lemongrass extract alone
and in combination with standard chemotherapy drugs FOLFOX and taxol for 48 hours then
subjected to inverted fluorescent microscopy (Figure 4). Green (AV) and red (PI) staining were
used as markers of apoptosis and are especially prominent in the treatment groups. Bright-field
images also show cell shrinkage and membrane blebbing as indicators of cell death.

Figure 4: Lemongrass extracts induce a change in colorectal cell morphology. HCT 116 (A) and HT-29 (B) cells were
treated with chemotherapeutics FOLFOX and taxol individually and in combination with 0.025 mg/mL lemongrass extract
and assessed at 48 hours. Fluorescence microscopy images of individual hibiscus treatments. Top panels: Brightfield and
fluorescent merged images at 400x magnification. Bottom: Fluorescent images stained with Annexin V (green), PI (red), and
Hoechst (blue) at 400× magnification. Scale bar is 50 microns. Images are representative of three independent experiments.
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Lemongrass extract is able to induce apoptosis in CRC cells by increasing oxidative stress.
LGE is an extract composed of many compounds able to interact in a complex manner.
Determining the method of apoptosis induction will allow for a greater understanding of how these
complex extracts show the observed anticancer potency. In order to determine if LGE is able to
induce apoptosis in CRC through induction of oxidative stress, H2DCFDA was used to monitor
the generation of ROS in CRC cells treated with FOLFOX in the presence or absence of LGE.
Indeed, it was observed that individual LGE treatment was able to induce significant ROS
generation in treated cells (Figure 5A). The combination sample of FOLFOX and LGE showed an
increased capability to generate ROS compared to FOLFOX alone.

Figure 5: Lemongrass extract induces oxidative stress on colorectal cancer and enhances FOLFOX oxidative stress
induction. HCT 116 and HT-29 colorectal cancer cells were treated with FOLFOX individually and in combination with 0.025
mg/mL lemongrass extract and assessed at 3 hours post-treatment against a positive control of hydrogen peroxide (H2O2).
Results were obtained using image-based cytometry to assess the percentage of cells positive with fluorescence associated
with the generation of reactive oxygen species (H2DCFDA, fluoresces green). Values are expressed as a mean ± SD from
three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison. *p <
0.05 vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control, @p<0.05 vs. Individual Chemotherapy Treatment.
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Lemongrass extract causes depolarization of the mitochondrial membranes in CRC cell
lines.
Although cell death mechanisms involving ROS and caspase activation were eliminated as
activators of apoptosis in colorectal cancer cells, the release of other apoptogenic factors from the
mitochondria may result in the induction of apoptosis. To monitor mitochondrial stability and
depolarization, the fluorescent tetramethylrhodamine methyl ester (TMRM) assay was used.
TMRM molecules accumulate in mitochondria with an intact mitochondrial membrane potential
(MMP). HCT 116 and HT-29 cells were treated with the respective treatment groups and incubated
for 48-hours and results were obtained using image-based cytometry. Interestingly, lemongrass
extract exhibited an even greater ability to disrupt MMP than the positive controls taxol and
FOLFOX, relative to the DMSO control (Figure 6).

Figure 6: Lemongrass extract enhances chemotherapeutic ability to reduce mitochondrial membrane potential. HCT
116 and HT-29 colorectal cancer cells were treated with FOLFOX individually and in combination with 0.025 mg/mL
lemongrass extract and assessed at 48 hours. Results were obtained using image-based cytometry to assess the percentage of
cells positive with fluorescence associated with mitochondrial membrane potential (TMRM, fluoresces red). Values are
expressed as a mean ± SD from three independent experiments. Statistical calculations were performed using Two-Way
ANOVA multiple comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control, ****p < 0.0001 vs. Control, @p<0.05 vs.
Individual Chemotherapy Treatment.
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Oral administration of lemongrass extracts reduces the tumour burden in colon cancer
xenograft models in immunocompromised mice and enhances the efficacy of FOLFOX
To confirm LGE efficacy, we wanted to investigate if these extracts have the ability to
inhibit the growth of colon cancer cells xenografted in immunocompromised mice and potentially
enhance the effects of FOLFOX. HCT 116 and HT-29 cells were transplanted subcutaneously in
mice. After tumour establishment, treatment groups were separated into groups and orally
administered either vehicle supplemented drinking water (control group), or LGE supplemented
drinking water for four weeks. FOLFOX and FOLFOX with LGE groups were administered
weekly intraperitoneal injections of FOLFOX. Indeed, LGE was able to reduce the tumour burden
of the xenografted mice as determined by tumour volume and weight compared to vehicle controls
(Figure 6A-B). Interestingly, LGE supplemented FOLFOX groups showed the largest reduction
in tumour burden compared to control (Figure 7A-B). Over the course of treatment, there was no
apparent change in the mice body weight gain in each treatment group when compared to controls,
indicating that these treatments were well tolerated (Figure 7C).
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Figure 7: Lemongrass extract administered orally reduces the tumour burden on colorectal cancer xenografted mice
and enhances FOLFOX efficacy. HCT 116 (A) and HT-29 (B) colorectal cancer cells were xenografted onto
immunocompromised mice hind flanks subcutaneously. After tumour formation, these mice were orally administered
lemongrass extract for 8 weeks. After 4 weeks, FOLFOX was administered subcutaneously once a week. After mice were
sacrificed, tumours were excised and measured for volume (using the formula ½*(L*W2) to calculate approximate volume).
(C) Mouse body mass was measured once a week and averaged to compare between experimental groups. Statistical
calculations were performed using One-Way ANOVA multiple comparison. *p < 0.05 vs. Control, **p < 0.01 vs. Control,
****p < 0.0001 vs. Control. No markings indicate non-significance vs. Control.
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4.4

Discussion and Conclusions
In order to test the ability of LGE to induce apoptosis we used annexin V and PI as staining

markers for early and late stage apoptosis, respectively. Two colorectal cancer (CRC) cell lines
were treated with increasing doses of lemongrass and assessed at 48 hours (Figure 1). In the HCT
116 cell line, apoptosis and necrosis induction were observed at doses as low as 0.025 mg/mL in
a dosage dependent manner. The more aggressive HT-29 cell line also responded to LGE with
reduced cell viability but did not do so in a dose-dependent manner. Both cell lines showed
comparable cell death percentages between the lowest dose of lemongrass extract (0.025 mg/mL)
and 1 μM staurosporine, an agent known to induce apoptosis at low doses (Figure 1).
Importantly, we additionally tested LGE at concentrations toxic to CRC cells on a normal
colon cell line, NCM-460. These cells are healthy and not cancerous and provide an in vitro model
for testing to see whether the extract is selective for cancer and able to avoid having detrimental
effects on healthy cells tissues. Interestingly, NCM-460 cells did show any significant decrease in
viability even at the highest dose of 0.1 mg/mL (Figure 2) indicating that LGE has no significant
effect on normal colon cells. However, it is important to note that staurosporine also did not cause
induction of apoptosis which may indicate that this cell line could be more resistant to chemical
agents and could explain why LGE did not cause induction of apoptosis. To mitigate this, other
healthy cell line models should be used to confirm this result. However, the selectivity of LGE as
proposed by these results supports previous findings wherein the same extract did not cause a
decrease in cell viability of NCM-460 cells, normal human fibroblast cells, and peripheral blood
mononuclear cells [6]. Therefore, these results indicate that lemongrass extract induces selective
apoptosis in colorectal cancer cells with no significant effect on normal healthy cells.
It is unlikely that NHPs will eventually be prescribed and used as singular treatments in
cancer therapy approaches. Current approaches to treating cancer rely on the usage of multiple

115

therapeutics to target multiple vulnerabilities of cancer cells [9]. As mentioned, oncologists are
hesitant to promote the usage of NHPs alongside chemotherapeutics due to the risk of negative
interactions. Thus, it is critical to examine whether LGE, if taken as an adjuvant to
chemotherapeutic drugs will enhance or inhibit their anticancer effects.
After treating HCT 116 and HT-29 cells with FOLFOX and taxol alone and in combination
with LGE, cells were stained with AV and PI dyes as indicators of apoptotic induction. In HCT
116 cells, LGE in combination with FOLFOX resulted in statistically significant enhancement of
anticancer efficacy. However, combination treatment with taxol did not affect cell viability relative
to the individual taxol treatments (Figure 3). In HT-29 cells, FOLFOX and taxol treatments in
combination with LGE did not show a statistically significant difference in apoptotic induction
when compared to the individual treatments (Figure 3). Both cell lines showed increased cell death
at the 96-hour time point, indicating that lemongrass may act in a time-dependent manner (Figure
3). Morphological changes such as membrane blebbing and cell shrinkage in addition to AV and
PI staining in treatment groups using fluorescent microscopy (Figure 4). These results
complemented the results presented previously and showed no decrease in apoptosis-related
markers in combination groups. In general, LGE did not cause an increase in efficacy at inducing
apoptosis when used in combination with FOLFOX and taxol. However, it is important to note
that LGE did not inhibit the ability to induct apoptosis of FOLFOX and taxol.
This result may seem counterintuitive due to a lack of any enhanced efficacy observed in
LGE combination treatments. However, our research group has reported beneficial effects of using
LGE in combination with chemotherapeutics including taxol (reported in Chapter 2). Our
investigation of LGE indicates that the efficacy of taxol would not be inhibited in CRC. Thus,
patients who may have cases of prostate cancer metastases may benefit from LGE treatment should
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the colon be the secondary site. It is responsible to report that LGE does not have a significant
ability to enhance FOLFOX and taxol in CRC cell lines.
The induction of apoptosis by LGE has not yet been characterized. The induction of
apoptosis by LGE may be dependent on the extract’s ability to induce oxidative stress. Indeed,
LGE treatment induced significant generation of ROS in both CRC cell lines and enhanced the
ability of FOLFOX to induce oxidative stress (Figure 5). However, the difference in ROS
generation could be primarily due to the action of LGE, indicating the need for further analysis to
conclusively analyze the true cause of this enhancement. The induction of caspase-independent
apoptosis is dependent on the permeabilization of the outer mitochondrial membrane. If LGE
apoptotic induction is dependent on mitochondrial membrane permeabilization, this may shed light
on the specific cancer cell targets and give insight into how these extracts are selective. HCT 116
and HT-29 cells were treated with LGE alone and in combination with FOLFOX and taxol to
assess effect of LGE treatment on mitochondrial membrane potential. LGE treatment led to drastic
decrease in the mitochondrial membrane potential and was able to enhance the ability of FOLFOX
and taxol to dissipate the MMP (Figure 6). This indicates that the chemotherapeutics treatments
do not inhibit LGE action on the mitochondria.
It is important to investigate the effects of LGE on a more complex in vivo mouse model
to assess its anticancer efficacy and identify potential toxicities in treatment. Immunocompromised
mice were xenografted with human CRC cells and orally administered LGE alone or alongside
FOLFOX intraperitoneal injection. Interestingly, LGE was able to reduce the tumour burden on
all mice at a comparable level to FOLFOX injections (Figure 7A-B). Further, LGE in combination
with FOLFOX injections reduced the tumour burden compared to LGE and FOLFOX treatments
alone. This result is interesting due to the lack of significant enhancement observed in vitro on
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CRC cell models. This may indicate that, at the animal level, LGE’s effects may be complex and
sensitize mice to FOLFOX treatment. In addition, LGE treatment groups showed similar weight
gain profiles with control mice, indicating that that treatment was generally well-tolerated (Figure
7C). Looking at FOLFOX injected mice, mice weight gain halted once injection treatments began,
indicating that mice suffered adverse effects to treatment such as loss of appetite. However, oral
administration of LGE was able to mitigate this effect in FOLFOX injected mice, as shown by
similar weight gain profiles of these mice. These results indicate that the active bioactive
compounds in these extracts were absorbed and stable when consumed, inhibited tumour growth
on the subcutaneous tumour xenograft site, and are well-tolerated for general consumption.
Conclusions
Lemongrass extract shows great potential as an anticancer agent in colorectal cancer
models. When used alone or in combination with conventional chemotherapeutics, low dosages of
lemongrass selectively induce apoptosis in CRC and do not inhibit cytotoxic effects of the other
drugs. LGE was able to enhance the ability to generate oxidative stress and dissipate of the
mitochondrial membrane potential when used in combination with FOLFOX and taxol, however
these results require further testing to identify whether or not this happens in healthy cell lines. In
xenografted mice models of colon cancer, LGE was able to significantly reduce the tumour burden
in mice, enhance the efficacy of FOLFOX, and reduce drug-related side effects. Ultimately, LGE
has shown to be a well-tolerated treatment option for CRC that does not inhibit the effect of
conventional therapeutics.
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5.1

General Discussion
Prior to the last decade, there has been a lack of rigorous scientific investigation into NHP

usage and a heavy dependence on anecdotal evidence. This has resulted in many oncologists being
hesitant to recommend the usage of NHPs due to a lack of valid scientific representation and the
risk of negative interactions with other treatments. However, research into natural products has
come to the forefront in part due to the ability of NHP phytochemicals to exhibited anticarcinogenic activities by interfering with the initiation, development and progression of cancer
[1]. Bioactive extracts of NHPs may be associated with reduced risk of adverse side effects due to
their traditional and wide usage. If these NHPs are used in combination with other
pharmacologically active compounds, they may reduce the drug-related toxicity and allow for an
increase in treatment efficacy [2]. Interestingly, 3 in 4 of every anticancer drug approved in the
last 80 years have been obtained either directly from natural products or as derived analogs of
natural product compounds [3]. Further, over 130 natural product-derived treatments are current
undergoing clinical trials to potentially be brought forward to market [4]. However, before
labelling any NHPs as safe for consumption and effective against cancer, studies with strong
scientific backing must be conducted.
In this body of work, the usage of NHPs as a therapeutic approach for cancer treatment was
validated in a reproduceable and unbiased manner. We identified three interesting NHP extracts
that merited further investigation of their anticancer effects, dandelion root extract (DRE),
lemongrass extract (LGE), and hibiscus extract (HE). Our group’s previous research on these
extracts indicated that these extracts induce selective cancer cell death in multiple models of cancer
[5,6]. However, the effects of DRE and LGE on prostate cancer, HE on breast cancer, and LGE on
colon cancer have yet to be investigated. Thus, a large portion of my research focussed on the
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ability and mechanism of apoptotic induction in these extracts using in vitro cancer cell models
and more complex in vivo mouse models. Further, the interactions of these extracts with common
chemotherapeutics have not yet been determined. In order to allow for further progression of NHPs
as cancer therapeutics, studies must show that these treatments are capable of being used as
adjuvants in combination therapies. This is due to the fact that current treatment approaches use
multiple chemotherapeutics to target various cancer cell vulnerabilities. This work also aimed to
identify whether or not DRE, LGE, and HE are able to have any significant interaction with
chemotherapeutics.
Our findings indicate that DRE, LGE, and HE have significant anticancer efficacy on
various cancer types. We determined that DRE was less efficacious on prostate cancer compared
to previous findings showing its efficacy on cancers such as leukemia, pancreatic cancer, and colon
cancer. Though still capable of inducing apoptosis in prostate cancer, this effect was not seen in a
significant manner until 96 hours post-treatment. This may be explained due to increased drug
resistance observed in prostate cancer as the diseases progresses towards a metastatic state [7].
Further, this could be explained due to differences in cancer cell vulnerabilities leading to variation
in responses to certain treatments. The induction of apoptosis was determined to be caspasedependent which is consistent with previous findings. Further research should investigate into
whether or not DRE can target the mitochondrial membrane to permeabilize and release proapoptotic factors, eventually resulting in caspase-dependent apoptosis. LGE was shown to be
extremely effective in a dosage-dependent manner on both prostate and colorectal cancer models.
In both cases, apoptotic induction was heavily dependent on the generation of reactive oxygen
species to induce oxidative stress on cancer cells. Many treatments targeting to induce oxidative
stress are known to be capable of overcoming cancer cell oxidative stress defence mechanisms to
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ultimately induce cell death [8]. Finally, HE induced potent apoptosis on both estrogen-receptor
positive and triple-negative breast cancer cells. Triple-negative breast cancer cells are notoriously
resistant to treatment and this discovery is substantial in validating the anticancer efficacy of
NHPs.
Current chemotherapeutic treatments for cancer are not selective and will adversely affect
normal healthy cells. This is due to generalized targeting of cancer cells, resulting in normal cells
being affected by treatment as well. For example, tubulin-targeting therapeutics may target the
tubulin of any cell showing not only potent anticancer efficacy due to the rapid growth and reliance
of cancer cells on tubulin, but also in normal healthy cells which rely on tubulin as well [9]. Many
of the drug-related toxicities and side effects stemming from chemotherapeutic treatments are
unable to be avoided [10]. In all cases, DRE, LGE, and HE showed no significant toxicity on
normal healthy cells at concentrations that would otherwise toxicity in cancer cells. This indicates
that these treatments have the ability to be well-tolerated if taken by humans.
The development of well tolerated anticancer agents able to synergize with chemotherapies
is essential to allow for a reduction in concentrations of toxic drugs used with no loss in therapeutic
success. In prostate cancer, we identified that DRE is able to enhance the efficacy of mitoxantrone,
and that LGE is able to enhance the efficacy of both taxol and mitoxantrone. In breast cancer, we
identified that HE is able to enhance both taxol and cisplatin in resistant triple-negative cells. It is
also important to note that treatments of DRE, LGE, and HE were able to reduce the cytotoxic
effects of chemotherapy treatment on normal healthy non-cancerous cells compared to
chemotherapy treatment alone. This indicates that these extracts may not only enhance
chemotherapy effects on cancer but protect normal cells from cytotoxicity. In colon cancer, LGE
was not determined to significantly enhance FOLFOX or taxol aside from at one timepoint for
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FOLFOX. However, none of these extracts inhibited the effect of chemotherapies on cancer
indicating that they should be safe to be used in combination. Interestingly, LGE and HE
combination treatments with chemotherapies enhanced their ability to significantly increase ROS
production and reduce mitochondrial membrane potential. This may explain why these extracts
are capable of synergizing with other treatments. These extracts may play a role in sensitization of
cancer cells through the generation of oxidative stress, allowing for a loss of defence mechanisms
against drugs, leading to enhanced apoptosis.
To better understand anticancer efficacy, in vivo studies were carried out on tumour
xenografted mouse models. Although these NHPs have been used for centuries with no adverse
effects reported, proper scientific validation on a more complex model of cancer is required. In
this work, we show that DRE and LGE were able to significantly reduce the tumour burden on
prostate cancer xenografted mice. We further show that LGE is also able to significantly reduce
the tumour burden on colorectal cancer xenografted mice. These results show that the complex
mixtures of DRE and LGE are able to be absorbed through the gastrointestinal tract and can be
brought to tumour sites to exert their effects. In all cases, DRE and LGE oral administration to
mice did not significantly decrease their weight gain profiles, indicating that these extracts were
well-tolerated. Further, LGE treatment in colon cancer mice was surprisingly able to enhance the
efficacy of FOLFOX and reduce related-toxicity. This is conflicting with in vitro results indicating
that LGE and FOLFOX did not show significant synergy at 96 hours. This could be explained due
to the fact that readily available water may have led to increased LGE consumption by mice,
indicating that higher dosages of LGE may synergize well with FOLFOX. Another explanation
could be that LGE consumption boosts the appetite of mice, explaining the mitigation of weight
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loss in mice injected with FOLFOX. Due to an increase in mouse health, an improved ability to
reduce tumour burden may have been observed.
Natural health product extracts are made up of complex mixtures containing multiple
pharmacologically compounds. We have shown in our previous work that the isolated bioactive
compounds of DRE and LGE were ineffective in inducing apoptosis when used individually. This
indicates that these extracts may rely on multiple phytochemicals interacting and working together
to target multiple vulnerabilities of cancer cells. This lends support to the notion that due to their
ability to target characteristics that are selective for only cancer, these extracts are well-tolerated
and suitable to be brought to market for human consumption.
This work provides sufficient evidence that DRE, LGE, and HE are highly effective and
selective anticancer therapeutics that are able to synergize and interact positively with many
common chemotherapies. Further, these extracts are able to drastically reduce the tumour burden
on xenografted mice while exerting no side effects and even protecting mice against toxicity by
chemotherapies. These NHPs further provide the essential scientific validation required to support
the development of safer and less expensive approaches to cancer treatment.
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5.2

Future Directions
The results presented in this thesis indicate that NHPs are promising anticancer therapies.

However, there is still much work needed to move these NHPs from the preclinical stage to the
market to be used to benefit patients.
Future work on this project should involve the determination and characterization of
pharmacologically active components in DRE, LGE, and HE. Although some work has been done
to identify these components, investigations looking at which combinations of phytochemicals
induce significant anticancer efficacy will allow for better understanding of the mechanisms of
NHP action. By doing so, we can identify mixtures of phytochemicals that are able to be developed
into novel cancer therapeutics and brought forward as well-tolerated chemotherapeutics.
Further work into determining the mechanism of actions of these complex NHPs will allow
for the identification of novel cancer vulnerabilities, allowing for the development of targeted
treatments able to improve the selectivity of these treatments. This could be accomplished with
gene or protein expression analysis to identify which specific cancer cell processes are triggered
via NHP-mediated apoptosis. In doing so, we can design treatments able to enhance this effect and
isolate them to only cancer cells.
These NHPs should be further studied with other chemotherapies and cancer types to
identify a full profile of what cancers and therapies are able to benefit from NHP usage. This
requires more rigorous research into drug-drug interactions and in vivo mouse studies to assess the
efficacy and toxicity of these treatments. As mentioned, many natural compounds have progressed
to clinical trials. As we investigate NHPs at the pre-clinical and clinical stage, more scientifically
sound research will result in a wider acceptance and development of NHPs as clinically valid
treatment approaches.
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5.3

Conclusions
Herein, we have presented work that significantly contributes to the scientific validation of

NHPs and their roles in cancer treatment. This work has provided support that NHPs are capable
of reducing cancer viability at cellular and animal model levels with no significant toxicity to
healthy non-cancerous cells. These NHPs may also be used with chemotherapeutics to enhance
their effect or reduce their toxicity to normal cells. Our work has indicated that the natural health
products dandelion root, lemongrass, and hibiscus have the potential to be further investigated and
brought to market for patient usage. Collectively, this study has demonstrated the importance of
natural health products in the development of well-tolerated and effective anti-cancer treatments.
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